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Role of mutations in the phosphoprotein on RNA polymerase activity of 
canine distemper virus following cell culture adaptation 
 
The canine distemper virus A75/17 wild-type strain, which is unable to replicate in cell lines, 
was adapted to growth in Vero cells. Sequence comparison between the A75/17 and the Vero 
cell-adapted A75/17-V virus revealed 7 amino acid differences between the 2 viruses. Three 
of these were located in the matrix protein, three in the phosphoprotein also changing the V 
protein but not the C protein and one in the large protein. The phosphoprotein and the large 
protein constituted the viral RNA polymerase whose activity was studied by transfection 
experiments using a reverse genetic system with a plasmid encoding a minireplicon and 
expression plasmids encoding the nucleocapsid protein and the viral RNA polymerase 
subunits. Surprinsingly, the enzyme of A75/17 CDV was significantly more active in cell 
lines compared to the polymerase of A75/17-V CDV. The decrease in overall enzyme activity 
was found to be due to both decreased replication and transcription activity. This polymerase 
attenuation was confirmed in CHO cells infection stably expressing the dog SLAM receptor 
mainly found in dog’s lymphoid organs and allowing both virus strains to enter these cells at 
the same efficiency. A75/17-V CDV replicated more slowly in CHODogSLAM cells than 
A75/17 CDV and syncytium formation was significantly decreased compared to A75/17 
infected CHODogSLAM cells.. Cell culture adaptation lead to an attenuated virus strain both 
in vitro and in vivo with decreased polymerase activity and syncytium forming capability 
showing an important role of the polymerase in determining the phenoytpe of the virus. In 
addition, this reduced phenotype of A75/17-V CDV was shown to be due to the P mutations 
in the P protein only, showing an important function of the polycistronic P gene in the 
adaptation process. 
The role of the matrix protein was found not to have any effect on polymerase activity, 
however its participation in the adaptation process still needs to be elucidated. 
The accessory proteins V and C were shown to act on polymerase activity, but their functions 
in virus pathogenicity and in inhibiting the interferon system have not been studied in this 
thesis. The V proteins have an activating effect on the polymerase of both the A75/17 and the 
A75/17-V CDV strains. 
Although the C protein amino acid sequence was not changed during adaptation of wild-type 
canine distemper virus in Vero cells, the C protein was demonstrated to have opposite effects 
on polymerase activity of both virus strains suggesting a different interaction of the C protein 
with the proteins forming the polymerase complex, which could modulate polymeras activity. 
These effects were demonstrated by transfection experiments and studying recombinant 
viruses not expressing the C protein. Thus, the abrogation of the C protein decrease the 
activity of the wild-type polymerase. In contrast, the polymerase activity of the Vero cell-
adapted virus is enhanced in the absence of the C protein and this has also been demonstrated 
with a recombinant virus, which grew faster in the first 48 hours of infection. 
Future studies will focus on the generation of recombinant wild-type viruses, which should be 
very helpful in understanding the molecular mechanisms underlying the adaptation process 
and the loss of pathogenicity. 
 
 
 II
Rôle des mutations dans la phosphoprotéine sur l’activité de l’ARN 
polymérase du virus de la Maladie de Carré suite à l’adaptation en culture 
de cellules 
 
La souche virulente A75/17 du virus de la Maladie de Carré n’est pas capable de se répliquer 
dans les lignées cellulaires et a été adaptée aux cellules Vero. La comparaison de séquences 
entre A75/17 et la souche adaptée A75/17-V montre sept nucléotides de différence. Trois des 
ces mutations sont localisées dans la protéine matricielle, trois dans la phosphoprotéine, 
changeant aussi la séquence de la protéine V, mais pas de la protéine C, et une dans la grande 
protéine. La phosphoprotéine et la grande protéine forment le complexe de l’ARN polymérase 
dont l’activité a été étudiée utilisant un système de génétique inverse; ce système consiste en 
la transfection de plasmides codant pour un miniréplicon, pour la nucléoprotéine et pour les 
protéines composant l’ARN polymérase. Etonnamment, la polymérase du virus A75/17 
présente une plus grande activité que celle de la polymérase du virus A75/17-V. Cette 
diminution d’activité est due à une diminution au niveau de la transcription et de la 
réplication. L’atténuation de la polymérase du virus A75/17-V a été confirmée au niveau viral 
lors de l’infection de cellules CHO exprimant stablement le récepteur canin SLAM situé sur 
les organes lymphatiques du chien et permettant l’entrée de ces deux virus avec la même 
efficacité. Le virus A75/17-V se multiplie plus lentement dans les cellules CHOSLAM que le 
virus A75/17 et a perdu la capacité d’induire des syncytia dans ces cellules. 
L’adaptation en culture cellulaire a donné naissance à un virus atténué autant in vitro qu’in 
vivo avec une activité de polymérase et une capacité de former des syncytia réduites 
démontrant un rôle important de la polymérase dans le phénotype du virus. De plus, cette 
activité de polymérase réduite est uniquement due aux mutations apparues dans la 
phosphoprotéine. 
Les mutations de la protéine matricielle n’influencent aucunement l’activité de polymérase 
des deux virus, par contre le rôle exact de cette protéine dans l’adaptation reste à être 
déterminé. 
L’activité de la polymérase a également été déterminée en présence des protéines accessoires 
V et C. Les protéines V ont un effet activateur sur l’activité de polymérases des deux virus 
A75/17 et A75/17-V. En ce qui concerne la protéine C, bien qu’elle ne contienne aucune 
différence au niveau protéique entre les virus A75/17 et A75/17-V, elle présente des effets 
opposés sur l’activité des polymérases virales. Ceci peut être attribué à une différence au 
niveau de l’interaction de la protéine C avec les complexes protéiques formant les 
polymérases virales. Ces effets ont été montré par des tests de transfection, mais aussi par la 
génération de virus recombinant pour la souche A75/17-V n’exprimant pas la protéine C. En 
résumé, l’élimination de la protéine C diminue drastiquement l’activité de la polymérase du 
virus virulent et augmente significativement celle de la polymérase du virus adapté. 
L’augmentation d’activité a été confirmée par un virus recombinant délété de la protéine C 
qui se multiplie plus rapidement dans les cellules Vero durant les premières 48 heures 
d’infection. 
Des études futures se focaliseront sur la génération de virus recombinant de la souche 
virulente de la Maladie de Carré afin de comprendre les mécanismes moléculaires du 
processus d’adaptation et de la perte de pathogénicité du virus adapté aux cellules Vero. 
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1. INTRODUCTION 
1.1 CLASSIFICATION 
Canine distemper virus belongs to the order Mononegavirales, including viruses with 
monpartite negative-sense RNA genomes and to the Paramyxoviridae family, which include 
some of the major and ubiquitous disease-causing viruses of humans and animals. This family 
has been reclassified in 2000 by the International Committee on the Taxonomy of Viruses 
into two subfamilies, the Paramyxovirinae and the Pneumovirinae (5). 
Paramyxovirinae contains three genera, Respirovirus, Rubulavirus, and Morbillivirus and the 
Pneumovirinae subfamily is divided into the Pneumovirus and Metapneumovirus genera. The 
new classification is based on morphologic criteria, the organization of the genome, the 
biological activities of the proteins, and the sequence relationship of the encoded proteins. 
The morphologic distinguishing feature for the subfamily Paramyxovirinae is the size and 
shape of the nucleocapsids, which have a left-handed helical symmetry. The biological 
criteria are on one hand the antigenic cross-reactivity between members of a genus and on the 
other hand, the presence (Respirovirus and Rubulavirus) or absence (Morbillivirus) of 
neuraminidase activity. 
The Pneumovirinae can be distinguished from Paramyxovirinae morphologically, as they 
contain narrower nucleocapsids. In addition, there are major differences in the number of 
encoded proteins and differences in the attachement protein. 
 
1.1.1 The Paramyxoviridae family  
The Paramyxoviridae are enveloped, negative-stranded RNA viruses that have special 
relationships to two other families of negative-strand RNA viruses, namely the 
Orthomyxoviridae (for the biologic properties of the envelope glycoproteins) and the 
Rhabdoviridae (for the similarity of organization of the nonsegmented genome and its 
expression).  
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Table 1: Examples of members of the Paramyxoviridae family 
Family Paramyxoviridae 
 Subfamily Paramyxovirinae 
  Genus Respirovirus 
   Sendai virus (mouse parainfluenzy virus type 1) 
   Human parainfluenza virus types 1 and 3 (hPIV 1/3) 
   Bovine paainfluenza virus type 3 (bPIV 3) 
  Genus Rubulavirus 
   Simian virus 5 (canine parainfluenza virus type 2 – SV5) 
   Mumps virus 
   Newcastle disease virus (avian paramyxovirus 1 – NDV) 
   Human parainfluenza virus types 2, 4a and 4b 
  Genus Morbillivirus 
   Measles virus 
   Dolphin Morbillivirus 
   Canine distemper virus 
   Peste des petits ruminants virus 
   Phocine distemper virus 
   Rinderpest virus 
 Subfamily Pneumovirinae 
  Genus Pneumovirus 
   Human respiratory syncytial virus (hRSV) 
   Bovine respiratory syncytial virus (bRSV) 
   Pneumonia virus of mice 
  Genus Metapneumovirus 
   Avian pneumovirus 
 Unclassified paramyxovirus 
   Tupaia paramyxovirus 
   Hendra virus 
   Nipah virus 
    
The Paramyxoviridae contain a lipid bilayer envelope that is derived from the plasma 
membrane of the host cell. The virus particles are generally spherical and 150 to 350 nm in 
diameter, but they can be pleimorphic, and filamentous forms can be observed. Inserted in the 
envelope are glycoprotein spikes that extend about 8 to 12 nm from the surface of the 
membrane and that can be readily visualized by electron microscopy and cause viral-cell 
membrane fusion at neutral pH. The nucleocapsid core is localized inside the viral membrane 
and contains the single-stranded RNA genome. The genomic RNA serves two functions: first 
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as a template for synthesis of mRNAs, and second as a template for synthesis of the 
antigenome (+) and for further copies of the (-) strand genomic RNA. Negative-strand RNA 
viruses encode and package their own RNA polymerase, but mRNAs are synthesized only 
after the virus has been uncoated in the infected cell. Holonucleocapsids (N:RNA plus P and 
L) have the capacity to transcribe mRNAs in vitro, and are thought to be the minimal unit of 
infectivity.  
 
1.1.2 The Paramyxoviridae genome 
The Paramyxoviruses contain nonsegmented, single-stranded RNA genomes of negative 
polarity. Their genomes are 15 to 19 kB in length and contain six to ten genes in tandem. The 
genomic RNA contains a 3’ extracistronic region of about 50 nucleotides (52 for CDV), 
known as the leader, and a 5’ extracistronic region of 38 to 161 nucleotides (38 for CDV), 
known as the trailer. These control regions flank the 6 genes and are essential in transcription 
and replication for the leader but only in replication for the trailer.  
The genome of canine distemper virus is 15’690 nt long and contains the genes encoding the 
nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the fusion protein 
(F), the attachment protein (H) and the large protein (L) as presented in figure 1. The P gene 
also encodes the C and V accessory proteins.  
 
 
Figure 1: Genome organisation of the Morbillivirus genus 
 
At the beginning and end of each gene are conserved transcriptional control sequences that 
are copied into mRNA. Between the gene boundaries are intergenic regions of precisely three 
nucleotides long for the Respiroviruses and Morbilliviruses but are quite variable in length for 
the Rubulaviruses (1 to 47 nucleotides) and Pneumoviruses (1 to 56 nucleotides). 
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1.2 VIRAL PROTEINS 
1.2.1 The polymerase complex 
1.2.1.1 The nucleocapsid protein 
The nucleocapsid (N) protein is the most abundant of the viral proteins and serves several 
functions in virus replication. It encapsidates the genome RNA into an RNase-resistant 
nucleocapsid, associates with the P-L polymerase during transcription and replication, and, 
most likely, interacts with the M protein during virus assembly. The N protein has the 
capacity to self-assemble onto a RNA template to form nucleocapsid-like particles in the 
absence of viral RNA and viral proteins (73).  
Encapsidation is initiated on specific sequences found within the leader RNA, whereas 
elongation of encapsidation occurs in an RNA sequence-independent manner. Each 
nucleocapsid protein is predicted to be associated with precisely 6 nucleotides. Presumably as 
a consequence of this association, paramyxovirus genomes are replicated efficiently only 
when they are a multiple of 6 nucleotides in length, and this has been dubbed “the rule of six” 
(33, 231). The intracellular concentration of unassembled N is thought to be a major factor 
controlling the relative rates of transcription and replication from the genome templates as 
studied for the rhabdovirus vesicular stomatitis virus (23, 24). 
The first large macromolecular aggregate found to self-assemble from its component parts 
was tobacco mosaic virus (TMV). In contrast to the plus-strand TMV RNA genome, which 
disassembles to function as mRNA and as a template for genome amplification, 
mononegavirus nucleocapsids never disassemble as far as we know; all RNA synthesis occurs 
here without reversing the structure of the N-RNA template. 
Paramyxovirus nucleocapsids are seen in remarkable detail in negatively stained electron 
micrographs, in which they appear as regular left-handed helical coils of ca. 200 Angström 
diameter with a central hole of ca. 50 Angström, ca. 1 µm in length, and with a pitch of ca. 60 
Angström. Mononegavirus nucleocapsids are generally more flexible than non enveloped 
RNA viruses such as TMV and open structures, however they must be very stable as the 
assembly survives the high salt conditions of CsCl density gradient centrifugation, at which 
they band at ca. 1.3 g/ml (or 2.5 M CsCl). This stability suggests that hydrophobic forces are 
important in maintaining the N-N and N-RNA interaction, and consistent with this, the N 
protein can be separated from the RNA only with the aid of ionic detergents like sodium 
dodecyl sulfate or 3M guanidine-HCl. 
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The N protein has been suggested to contain two domains. The N-terminal of the protein of 
about 400 residues, the NCORE, is relatively well conserved in sequence and resistant to 
proteolysis. The C-terminal part, the NTAIL, is hypervariable and protrudes from the surface of 
viral nucleocapsids (101, 102); it belongs to the class of the natively disordered proteins (27). 
While the NCORE contains all the regions necessary for self-assembly and RNA-binding (12, 
157), the NTAIL contains the regions responsible for binding to the phosphoprotein. 
Association of the phosphoprotein with the soluble monomeric form of N prevents its 
illegitimate self-assembly onto cellular RNA (113, 199) and this complex is the substrate used 
by the polymerase to initiate encapsidation of genomic RNA (52, 108). Consequently, the 
NTAIL is required for the N:RNA complex to act as a template for viral RNA synthesis (30, 49, 
235). 
Beyond its role in encapsidating viral RNA, the NTAIL likely interacts with the matrix protein 
(M) (45, 83). N interaction with intracellular partners also relies on the NTAIL: it binds to the 
interferon regulatory factor 3 (IRF-3) leading to the activation of the IFN α/β enhanceosome 
(220), whereas a conserved hydrophobic patch at the extreme C-terminus of Morbillivirus 
NTAIL has been described to bind to the heat-shock protein Hsp 72, which modulates the level 
of viral RNA synthesis (235). 
The N protein of about 62kDa is phosphorylated and this appears to regulate its function. Free 
N is phosphorylated on serine, whereas nucleocapsid-associated N is phosphorylated on 
serine and threonine (87).  
 
1.2.1.2 The phosphoprotein 
For the Paramyxovirinae, the P gene represents an extraordinary example of a virus 
compacting as much genetic information as possible into a small gene. Paramyxovirus P 
genes are polycistronic expressing proteins from at least two (and often all three) open 
reading frames (ORFs), the V, C, W and R proteins, which will be discussed in the following 
sections. 
The P protein of Paramyxovirinae plays multiple roles in both transcription and replication, 
being an indispensable subunit of the viral RNA dependent RNA polymerase (RdRp) 
complex. It enables the positioning of the large protein, which carries the polymerase activity, 
on the holonucleocapsid formed by the RNA and the nucleoprotein, as well as the binding and 
delivery of N proteins to the newly synthesized genomic RNA. 
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The phosphoprotein of paramyxovirus has a modular structure with two domains that are 
functionnally and structurally distinct: a C-terminal moiety (PCT) and a N-terminal moiety 
(PNT). PCT is the most conserved in sequence and contains all regions required for virus 
transcription, whereas PNT, which is poorly conserved, provides several additional functions 
required for replication (50). Figure 1(A) shows the general organization of P in all 
Paramyxovirinae, whereas figure 1(B) shows the organization of P in a representative 
member of each of the three main genera.  
 
 
Figure 2: General organization of the P protein of the Paramyxoviridae family 
 
P has a modular organization consisting of six distinct regions: a hydrophobic, N° binding 
region with a-helical potential, a disordered region of greatly variable length, a central region 
(overlapping the V ORF) that can be either ordered or disordered, a coiled-coil, a disordered 
linker and the X domain. 
PNT acts as a chaperone for newly synthesized N, so called N°, and prevents it from binding 
to non viral RNA in the infected cell through the NCORE (52). The main N° binding site has 
been mapped to the N-terminus of PNT in all Paramyxovirinae, rich in hydrophobic clusters 
associated with a clear α-helical propensity. This N-terminal part of PNT is followed by a 
region devoid of hydrophobic clusters. Structural investigations on the measles virus PNT 
have shown that it is not structured in solution. It thus belongs to the class of natively 
unfolded proteins, further confirming its reported similarity with acidic activation domains of 
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cellular transcription factors. This result was extended to several Morbillivirus PNTs and to 
Sendai virus PNT (118).  
Paramyxovirinae PCT share three common features: (i) oligomerization through a coiled-coil 
region sufficient for in vitro transcription (48), (ii) the presence at the exteme C terminus of a 
short predicted bundle of three α-helices, which is involved in binding to N (52), and (iii) the 
presence of an L binding site (49).  
The P protein of the related Sendai virus (SeV), a member of the Respirovirus genus, is 
tetrameric (217), whereas the oligomeric state of measles virus (MV) P protein is unknown. It 
is suggested that SeV P participates in both transcription and replication in its multimeric 
form, being tetrameric when complexed with both L and N°. 
The P protein functions as a transcriptional activator of the L protein and seems to 
transactivate the L protein for transcription in a similar way to that observed for eukaryotic 
transactivators. However, phosphorylation of the P protein seems to be a prerequisite for its 
transcriptional activity as demonstrated for many non-segmented negative-stranded RNA 
viruses. The P protein of vesicular stomatitis virus (VSV), Chandipura virus, respiratory 
syncytial virus (RSV), measles virus and rinderpest virus have been shown to be 
phosphorylated by casein kinase II (CKII). In the case of canine distemper virus (CDV), the P 
protein is predominantly phosphorylated by protein kinase C-ζ  (PKC-ζ) and CKII has a 
minor role (138). PKC-ζ mediated phosphorylation is essential for virus replication (138) and 
is also involved for sendai virus (114). Phosphorylation is located in the N-terminal part of the 
P protein and has been shown to mediate multimerization of the P protein that facilitates 
complex formation with the L protein by increasing the α-helical structures within the P 
protein (76). 
 
1.2.1.3 The large protein 
The L genes of most Paramyxovirus have now been sequenced and they are all of very similar 
length (about 2’200 amino acids). The L gene is the most promoter-distal in the 
transcriptional map and thus the last to be transcribed. Consequently, the L protein is the least 
abundant of the structural proteins (about 50 copies per virion) and is associated with the viral 
nucleocapsid in the cell and in the virion.  
The L protein, responsible for polymerase activity, contains the catalytic functions required 
for RNA synthesis. It is a multifunctional enzyme participating in initiation, elongation, 
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methylation, capping and polyadenylation of the RNA (104). L protein has also been found to 
exhibit kinase activity (66).  
Formation of the RNA polymerase requires the coexpression of the P and L proteins where P 
binding stabilizes the L protein, probably by facilitating the correct folding of L (108, 109). 
Recently, it has been shown that the L protein of Sendai virus is present as an oligomer in the 
P-L polymerase complex (197). The oligomerization site of the SeV L protein is located at the 
very N-terminal part of the protein (40) as well as the P and L binding sites (107), however, 
they are independent of one another. Based on the homology of the proteins, we predict that 
all paramyxovirus L proteins will also oligomerize as has already been demonstrated for 
Sendai and parainfluenza virus type 3 (PIV3) (198). Moreover, recent data have shown that 
the RNA polymerases of the positive-strand RNA viruses, poliovirus, and hepatitis C virus 
also require oligomerization for function (163, 175). 
Sequence alignment of the L proteins of viruses of the order Mononegavirales revealed six 
distinct regions of relatively high conservation, designated I to VI, from the N- to C-terminus 
of the protein, which were proposed to specify the essential activities common to all L 
proteins (14, 172, 194). 
The domains II, III and VI have motifs present in other RNA polymerases. While domain II 
has been shown to be responsible for RNA recognition, the domain III has the QGDNQ 
pentapeptide motif, which is thought to have the active site for phosphodiester bond formation 
(141). The GDN sequence is assumed to correspond to the GDD motif of positive strand RNA 
viruses and to M/V/IDD of retroviruses involved in polymerase function (196). It is thus 
thought that domains II and III constitute the active module for the viral RNA polymerase as 
mutations inactivate viral RNA synthesis (197). Mutations in domain I and V of SeV L have 
been shown to uncouple the transcription and replication (41, 46) and mutational analysis in 
domains IV and VI showed a defective RNA synthesis phenotype (70), thus indicating the 
importance of these domains in viral RNA synthesis. 
Sequence alignment within the Morbillivirus genus between measles (MeV), canine 
distemper (CDV), phocine distemper (PDV) and rinderperst (RPV) viruses show considerably 
more sequence identity compared to other negative strand virus genera. It reveals that 
conserved sequence motifs are not only restricted within the above-mentioned six domains 
but that the whole L protein is conserved. Three conserved boxes have been identified in the 
morbillivirus L proteins designated as boxes A (residues 1-606), B (residues 650-1694) and C 
(residues 1717-2183), separated by two hinge regions of low identity. The QGDNQ 
pentapeptide motif is located in box B at positions 771-775 flanked by hydrophobic residues 
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associated with many RNA-dependent RNA polymerases (172) and is important in viral RNA 
synthesis as demonstrated for RPV (42). 
 
1.2.2 The structural proteins 
1.2.2.1 The matrix protein 
The Paramyxovirus matrix (M) protein contains 341 to 375 residues (Mr 38’500 to 42’500 
Da), is quite basic and somewhat hydrophobic, although there are no domains of sufficient 
length to span a lipid bilayer. The M protein is thus peripherally associated with membranes 
without being an intrinsic membrane protein. It probably contains amphipathic α-helices that 
insert themselves into the inner leaflet of the lipid bilayer, to coat this surface and organize its 
contact with the helical nucleocapsid by interacting with the N protein (83). This association 
with the nucleocapsid serves two functions, which are genetically unrelated (71) : (i) it 
facilitates assembly and (ii) it inhibits the transcriptase activity of the nucleocapsid prior to 
encapsidation (45, 117).  
The nucleocapsid of negative-strand RNA viruses has to be rendered inactive before it can be 
packaged into the virus particle; this function has been attributed to the matrix proteins. The 
M protein associates with RNPs late in the virus life cycle in order to inhibit virus 
transcription, thus facilitating virus assembly. Vesicular stomatitis virus, measles virus and 
influenza virus matrix proteins interact with, and inhibit transcription of viral nucleocapsid in 
infected cells (35, 169, 209). The structural role of the M protein recently became more 
evident, as it was found that rabies virus M protein regulates the balance of virus transcription 
and replication, although it is not yet known whether it has RNA-binding capacity (72). In 
addition, the authors next identified mutations that affect the function of M only in regulation 
of RNA synthesis, but not in assembly and budding, providing evidence that these functions 
are genetically separated (71). 
The M protein also interacts with the cytoplasmic tails of the fusion and attachment proteins. 
Thus, the M protein is considered to be the central organizer of viral morphogenesis, 
interacting with the cytoplasmic tails of the integral membrane proteins, the lipid bilayer, and 
the nucleocapsids. The self-association of M and its contact with the nucleocapsid may be the 
driving force in forming a budding virus particle. The M protein promotes paramyxovirus 
budding by acting as a bridge between the nucleocapsid and the viral enveloppe. It was 
suggested that the M protein binds simultaneously to cellular actin and the viral RNPs, 
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facilitating transport of these viral structures to the plasma membrane into which the mature 
viral glycoproteins are inserted (85). 
The M protein is crucial in extracellular virus particle formation resulting in the formation of 
extracellular infectious virus or infectious filamentous structures that protrudes from infected 
cell membranes in the presence of F cytoplasmic tail. When expressed alone, M protein is 
able to bind cellular plasma membranes, which is stabilized by surface expression of the viral 
glycoproteins. Its colocalization with the F protein has been described in specific lipid rafts 
(103). 
 
1.2.2.2 The fusion protein 
The Paramyxovirus fusion proteins directly mediate viral penetration by fusion of the host 
cell membrane with the viral membrane at neutral pH enabling the ribonucleocapsid entry in 
the cell cytoplasm. Later in infection, the F proteins expressed at the plasma membrane of 
infected cells can mediate fusion with neighbouring cells to form syncytia (giant cell 
formation), a cytopathic effect that can lead to tissue necrosis in vivo and which might also be 
a mechanism of virus spread. 
Typical of paramyxovirus F proteins is that they are synthesized as an inactive precursor, F0, 
which is cleaved by a host-cell protease. This releases the new N-terminus of F1, thus forming 
the biologically active protein consisting of the disulfide-linked chains F1 and F2. The 
Paramyxovirus F genes encode 540 to 580 residues. The F proteins are type I glycoproteins, 
which span the membrane once and contain at their N-terminus a cleavable signal sequence 
that targets the nascent polypeptide chain synthesis to the membrane of the endoplasmic 
reticulum (ER). At their C-termini, a hydrophobic stop-transfer domain (a transmembrane 
domain (TM)) anchors the protein in the membrane, leaving a short cytoplasmic tail (about 20 
to 40 residues) (152). 
Comparison of the amino acid sequences of Paramyxovirus F proteins does not show overall 
major regions of sequence identity, but the similar placement of cysteine, glycine, and proline 
residues together with the overall hydrophobicity of the F proteins suggests a similar structure 
for all F proteins. The fusion proteins of several widely disparate viruses share several 
important common features. The Paramyxovirus F protein, the human and simian 
immunodeficiency virus (HIV and SIV) gp160, Ebola virus GP, and influenza virus 
hemaglutinin (HA) protein all form homotrimers that must be proteolytically cleaved to be 
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biologically active. This structure has been suggested to represent the final, most stable form 
of the protein, present either during or subsequent to membrane fusion (181). 
 
1.2.2.3 The attachment protein 
The hemagglutinin (H) protein of 617 amino acids is the receptor-binding protein and is an 
important determinant of Morbillivirus cellular tropism (203). It is a type II transmembrane 
glycoprotein and is located on the surfaces of infected cells and virions as a disulfide-linked 
homodimer. It acts in synergy with the F protein during fusion and entry of the virus in 
infected cells (122). In some systems, it is clear that the H protein once attached to its receptor 
activates the F protein (105). 
The H protein is folded and dimerized in the endoplasmic reticulum and its glycosylation is 
necessary for proper folding, antigenicity, dimerization, and export from the Golgi (111). 
The CDV H protein is very similar to the H protein of measles virus. However, it lacks the 
hemagglutinating activity.  
 
1.2.3 The accessory  proteins 
1.2.3.1 The V protein 
The V open reading frame is found in the middle of the P gene of all three genera of the 
Paramyxoviridae family. The V protein is expressed by all morbilliviruses and rubulaviruses, 
but only by some of the respiroviruses. In Sendai virus, bPIV-3, the morbilliviruses and NDV, 
the cysteine-rich V ORF is translated from an mRNA with a single G insertion, whereas in 
rubulaviruses the V protein is translated from the unedited mRNA. In either case, the resulting 
fusion protein is called V. The C-terminal portion of the V ORF is by far the most conserved 
of all the various P gene ORFs, even though the V ORF is absent in hPIV-1 and may not be 
expressed in hPIV-3. There are seven perfectly conserved cysteine residues, and this domain 
binds two atoms of zinc. The cysteine rich V domain of several viruses specifically interact 
with the large subunit of the cellular damage-specific DNA-binding-protein (UV-DDB), but 
the consequences of this interaction and the function of the V protein cysteine-rich domain 
remains to be elucidated.  
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1.2.3.1.1 RNA editing 
Most Paramyxovirus P genes contain a functional editing site at the start of the internal, 
overlapping V ORF. Transcription yields, in addition to faithful mRNA, edited versions that 
contain variable numbers of inserted G residues. For the morbilliviruses, respiroviruses, and 
NDV, which require a single nucleotide insertion to shift to the V ORF from the genome-
encoded P ORF, a single G is added, as the predominant editing event. 
For the Rubulaviruses (SV5), the edited version of the mRNA encodes the P protein and the 
unedited one is the V protein (221). 
As the Paramyxoviruses replicate in the cytoplasm, they must provide enzymes for all aspects 
of their mRNA synthesis. The RdRp polyadenylate mRNAs by stuttering on a short run of 
template U residues (four to seven nucleotides long) at the end of each gene (gene-start). By 
analogy to the polyadenylation mechanism, it was suggested that the G insertions at the 
specific site in the P gene would occur cotranscriptionally by  a stuttering mechanism (228). 
The specific recognition site is 5’ (A)5(G)3 3’ on the mRNA. 
The editing frequency has been determined for many viruses such as Sendai virus (31%), 
measles and rinderpest viruses (50%) (186). 
 
1.2.3.1.2 Morbillivirus V protein 
The V protein shares the initiator methionine and the 231 amino acids of the P protein. RNA 
editing adds an extra non-template-directed guanosine residue at position 751 following three 
genomically encoded Gs and results in a different carboxyl terminus. The last 276 amino 
acids normally encoded by the P mRNA are replaced with a cysteine-rich domain of 68 amino 
acids that has zinc-binding properties (137). 
The V protein is not associated with intracellular or released viral particles and has been 
found to be dispensable for measles virus propagation in cell culture (186). However, in the 
absence of the V protein, both measles-specific proteins and RNAs accumulated to levels 
higher than the parental measles virus (Edmonston strain). This is dependent on the 
interaction of the V protein with the N protein. These complexes compete with the complexes 
formed between the N and P proteins, thus lowering polymerase activity. In addition, the V 
protein may contribute to viral pathogenicity in vivo (222). 
Recently, the V protein of measles virus has been shown to block interferon-α/β but not 
interferon-γ signalling by inhibiting STAT1 and STAT2 phosphorylation (213). Moreover, it 
has been demonstrated to interfere with signalling by interleukin-6 and the non-receptor 
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tyrosine kinase v-Src and to directly associate with cellular STAT1, STAT2, STAT3, and 
IRF9, as well as several unidentified partners. This may provide a novel intracellular 
mechanism for measles virus-induced cytokine inhibition that links innate immune evasion to 
adaptive immune suppression (160). 
In the case of CDV, the existence of the V protein has first been demonstrated by Haas and 
colleagues in 1995 (96), but its function has not yet been identified. 
 
1.2.3.1.3 Sendai virus V protein 
The Sendai virus V protein has been found to regulate negatively viral genome RNA 
replication through its N-terminal domain (47), and its interaction with the NP protein (110). 
A recombinant devoid of mRNA editing has been compared to the parental wild-type sendai 
virus strain and has been found to be non essential in various cell lines in vitro (55), with 
augmented gene expression and cytopathogenicity. However, the V(-) virus was markedly 
attenuated in in vivo replication capacity and in pathogenicity for mice. Thus, as a non-
essential gene product, SeV V protein encodes a luxury function required for in vivo 
pathogenicity (119). In addition, the pathogenicity determinant in the V protein was mapped 
to the C-terminal half and the N-terminal half was probably sufficient to confer normal in 
vitro phenotypes (75, 112, 120). 
 
1.2.3.1.4  Simian virus 5 (SV5) V protein 
The V protein of SV5 is the most studied in the Paramyxoviridae family and corresponds to 
the nonedited protein of the P gene. In contrast, the P protein is obtained after a 
cotranscriptional editing of the P gene. The V protein of SV5 binds two atoms of zinc and is a 
structural component of the virion (164). The RNA-binding domain lies in the N-terminal part 
of the V protein through basic residues. This N-terminal domain is involved in inhibition of 
RNA synthesis by a competitive mechanism between V and P for N and RNA binding (133). 
The C-terminal part of the V protein called the zinc-finger domain interacts with cellular 
proteins as the damage-specific DNA binding protein (DDB) to slow down the cell cycle 
(132) and have an impact on pathogenicity; this interaction has been shown for SV5, mumps, 
hPIV2 and measles viruses (134). 
In contrast to Sendai virus, mice infected with SV5 showed no overt signs of disease. 
Evidence was presented that a major factor, which prevented SV5 from productively infecting 
mice was its inability to circumvent the interferon response in mice. Thus, in murine cells that 
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produce and respond to IFN, SV5 protein synthesis was rapidly switched off. In human cells, 
both SeV and SV5 inhibited the activation of an IFN-α/β-responsive promoter by targeting 
STAT1 for proteasome-mediated degradation through the V protein (56, 57, 234). Compared 
to SeV, SV5 has been shown to be a poor inducer of IFN-β due to the expression of an intact 
viral V protein and more precisely through the C-terminal cysteine-rich domain, a feature that 
is highly conserved among paramyxoviruses (173). A recombinant lacking the C-terminal part 
of the V protein was shown to produce IFN-β as a consequence of the formation of the ISGF3 
transcription complex allowing the translocation of the transcription factor IRF-3 to the 
nucleus (99). 
Thus, SV5 blocks two distinct pathways of the innate immune response (via STAT1 or IRF-
3), both of which require the presence of the C-terminal specific cysteine-rich domain of the 
multifunctional SV5 V protein. 
 
1.2.3.2 The accessory C protein 
1.2.3.2.1 Morbillivirus C proteins 
The C proteins are encoded by the same mRNA as the P protein, but they are translated using 
an initiator methionine codon 22 nucleotides downstream from that of P and translated in an 
overlapping reading frame. They are about 170 amino acids long, basic (pI of about 10.5) and 
poorly conserved. Morbilliviruses express one C protein as do the newly isolated Hendra 
virus and Nipah virus. The C proteins are found in the infected cells, but are not present in the 
virions. 
For Rinderpest virus, the C protein may play a role in RNA transcription as has been 
demonstrated by recombinant knock-out viruses for this protein, which grew more slowly 
than in the presence of the C protein (16). The C protein has been colocalized with the N, P 
and L proteins in infected cells and has been shown to interact with L and with itself forming 
large aggregates (210). 
The C protein of measles virus has been first discovered by Bellini and Richardson in 1985 
(20). It was shown to be non essential for Edmonston B vaccine strain for multiplication in 
cultured cell lines (176). However, it is required for an efficient virus replication in vivo (68, 
223), suggesting a function as a virulence factor in the host (165). In a CAT reporter 
minigenome assay, it has been demonstrated that the C protein inhibits viral RNA synthesis 
but to a different extent in the vaccine strain than in the wild-type strain (178). Finally, a 
recent study suggested that the measles virus C protein plays an important role in 
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pathogenesis by inhibiting IFNα/β signalling, which is part of the innate immunity to viral 
infections by inducing an antiviral response and by limiting viral replication until the adaptive 
response clears the infection (191). 
For canine distemper virus, the C protein has first been reported in 1986 and has not yet been 
extensively studied (201). Its function will be discussed in this thesis in the context of virus 
adaptation. 
 
1.2.3.2.2 Sendai virus C proteins 
Some viruses express multiple species of C protein, while others only express one as 
presented for the morbillivirus genus.  
An extraordinary case is Sendai virus (SeV), whose C ORF produces a nested set of C-
coterminal 4 proteins: C’, C, Y1 and Y2 (129, 130). These proteins are referred as the C 
proteins and are initiated at a non-AUG codon for C’ (ACG 81) upstream the AUG codon of 
the P protein (51, 95), at AUG 114 for C, AUG 183 for Y1 and at AUG 201 for Y2. They all 
are encoded by an ORF in the +1 frame relative to that of P (84, 192). Among them, C is the 
major species and is expressed in infected cells at a molar ratio several fold higher than the 
other three. The initiation codons of the C and C’ proteins are accessed by ribosome scanning 
from the cap structure, in contrast to the synthesis of the Y1 and Y2 proteins, which have 
been proposed to be synthesized by a ribosome shunt. 
The role of the negative-stranded virus accessory C proteins is difficult to assess because they 
appear as nonessential.  
On the other hand, when a function is found it represents an enigma, in that the C proteins 
inhibit viral mRNA synthesis (53) and replication under certain conditions depending on the 
promoter. Tapparel and colleagues showed in 1997 that replication of the genomic copyback 
defective interfering (DI)-H RNA is more sensitive to inhibition by C protein than is the 
synthesis of DI leader RNA (216). These inhibitions of mRNA synthesis and replication have 
been observed at the level of protein-protein interactions, where the C proteins have been 
shown to directly bind the L protein of the polymerase complex (109). 
In mice, the C proteins appeared to be required for multiple cycles of replication implicating 
some aspects of innate immunity and are thus indispenable for in vivo multiplication and 
pathogenesis (128). In addition, Sendai virus renders cells unresponsive to interferon-α/β by 
suppressing the induction of the IFN-α stimulated genes and the subsequent establishment of 
the antiviral state (89). This interaction with the interferon system has been extensively 
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studied by Garcin and colleagues. First, the C protein and not C’ has been determined as the 
protein responsible of the prevention of the antiviral state (79), and this by inducing STAT1 
instability or by interaction with cellular components (78). Furthermore, the nested set of C 
proteins was reported to interact with STAT1 to prevent IFN signalling through the Jak/Stat 
pathway. Nevertheless, only the longer C proteins reduced STAT1 levels and prevented IFN 
from inducing an antiviral state (77). 
In 2001, Takeuchi and colleagues first demonstrated that the C protein physically associates 
with STAT1 for the inhibitory control on the transcriptional activation of IFN stimulated 
genes (214), which has been attributed to the nested set of C proteins by Garcin and 
colleagues (80). In addition, the C protein-induced instability of STAT1 was accompanied by 
an unexpected hallmark of protein degradation by an increase in the level of mono-
ubiquitinated STAT1 (80). Recently, the STAT1 interaction with the C protein of Sendai 
virus appears to participate in the inhibitory process for STAT2 activation, which is a crucial 
target for the blocking of IFN-α signalling (88). 
Another important function has been assigned to the Y2 protein as having an antiapoptotic 
activity, which works in collaboration with the longer C proteins in order to suppress virus-
induced apoptosis in the SeV-infected cells (125). 
Finally, a very recent publication mentioned the possible role of the C protein in virus 
budding, by facilitating the release of virus-like particles. This role is complementary to the 
functions of the N, M, F and HN proteins (205). 
 
1.3 VIRAL LIFE CYCLE AND MULTIPLICATION 
The viral life cycle of Paramyxoviridae takes place in the cytoplasm of infected cells. 
 
1.3.1 Virus attachment and entry 
Upon attachment of the virus through the interaction of the H protein with its cellular 
receptor, the viral membrane fuses with the cellular plasma membrane at the neutral pH found 
at the cell surface. This results in the release of the helical nucleocapsids into the cell 
cytoplasm. In the viral particle the M protein is thought to make numerous contacts with the 
nucleocapsid, which have to be disrupted at the fusion step. For influenza virus, the difference 
in pH between the acidic uncoating compartment (endosomes) and the assembly site (plasma 
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membrane) is thought to alter the equilibrium between self-assembly and disassembly of the 
M-N complexes (4). The mechanism used for Paramyxovirus uncoating is not yet known. 
 
1.3.2 Viral RNA synthesis 
1.3.2.1 Primary transcription 
Intracellular RNA synthesis of paramyxoviruses begins with the viral RNA dependent RNA 
polymerase (RdRp) transcribing the N-encapsidated genome RNA into 5’ capped and 3’ 
polyadenylated mRNAs. The viral RdRp begins all viral RNA synthesis at the very 3’ end of 
the genome and it transcribes the genes into mRNAs in a sequential and polar manner by 
terminating and reinitiating at each of the gene junctions located in the intergenic regions. The 
junctions are called the regulatory elements and consist of a gene-end sequence, at which 
polyadenylation occurs by the reiterative copying of four to seven uridylates followed by the 
release of the mRNA. The gene-end is followed by a short non-transcribed intergenic 
sequence of 3 nucleotides, for respiroviruses and morbilliviruses, and by a gene-start 
sequence that specifies the capping as well as mRNA transcription initiation. 
The RdRp has first to transcribe the leader RNA before beginning mRNA synthesis at the N 
gene-start signal. A leader RNA termination site has not been demonstrated for any 
nonsegmented negative-strand RNA virus and it is thought that the RdRp reading through the 
leader-N junction may simply become nonprocessive, releasing its nascent chain. 
The RdRp occasionally fails to reinitiate the downstream mRNA at each junction, leading to 
the loss of transcription of further-downstream genes, and hence there is a gradient of mRNA 
synthesis that is inversely proportional to the distance of the gene from the 3’ end of the 
genome. The mRNAs produced are not encapsidated by the N proteins and are thus accessible 
by the ribosomes, which can translate them into new viral proteins. 
 
1.3.2.2 Viral replication 
Viral replication provides additional templates for transcription and allows amplification of 
the viral genome. This step requires that the RdRp enters an antitermination mode where it 
ignores all the intergenic regions. This results in the synthesis of a complementary copy of the 
negative-strand genome, called the antigenome. The antigenome is used only for replication, 
which starts at the antigenome promoter.  
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The switch of the RdRp from transcription to replication has been extensively studied and is 
thought to be regulated by the concentration of free N proteins in the cytoplasm of the 
infected cell. Once a sufficient amount of unassembled N proteins has been reached, the 
polymerase switches to replication, thereby lowering the levels of unassembled N proteins. 
For rabies virus, there is increasing evidence that other viral gene product (M gene) may also 
play a role (72). 
Genome synthesis from antigenome templates is thought to take place in a fashion similar to 
that of antigenome synthesis, in that the promoter at the 3’ end of the antigenome is 
functional. The newly replicated strands will be automatically encapsidated by multiple N 
proteins. For paramyxoviruses, the site for the initiation of genome and antigenome 
encapsidation has been mapped to the first 14 nucleotides of the leader and the trailer 
sequences, which are similar for all paramyxoviruses. For canine distemper virus, the OP-
CDV strain follows this rule, however the wild-type A75/17 as well as the Vero cell-adapted 
A75/17-V and the keratinocyte-adapted A75/17-K CDV strains are slightly different. There is 
indeed one nucleotide difference in the leader compared to OP-CDV, which does not disturb 
the encapsidation process. 
It is thought that the template is copied without dissociation of N proteins from the 
nucleocapsid, and the uncoiling of the nucleocapsid may be necessary for the polymerase to 
gain access to the RNA bases. It is possible that the viral polymerase traverses the 
nucleocapsid template by uncoiling the helix in front of it and recoiling it once the 
polymerase has passed a given position, much the same as cellular RNA polymerase 
generates its template “bubble” in traversing dsDNA (101). 
 
1.3.3 Virion assembly and release 
The intracellular site of nucleocapsid two-step assembly is the cytoplasm; first, the free N 
subunits associates with the genome to form the helical RNP structure, and second, the P-L 
protein complex associates to form the functional nucleocapsid structure. 
The assembly of the second part of the virus, the envelope, is at the cell surface. The viral 
integral membrane proteins are synthezised and undergo a step-wise conformational 
maturation in the endoplasmic reticulum before transport to the secretory pathway. Folding 
and conformational maturation of glycoproteins are assisted by numerous folding enzymes 
and molecular chaperones. Only correctly folded and assembled proteins are generally 
transported out of the endoplasmic reticulum. In the Golgi apparatus, the carbohydrate chains 
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may be modified and the F protein is cleaved. Finally, the glycoproteins are transported to the 
plasma membrane (152).  
At the plasma membrane, the viral M proteins are thought to play a major role in bringing the 
assembled ribonucleoprotein core to the appropriate place to form a budding virion. It is 
presumed that the glycoprotein cytoplasmic tails make important contacts with the M protein, 
which in turn, associates with the nucleocapsid (36, 37). However, the exact mechanism is 
still unknown. 
 
1.4 PATHOGENESIS OF CANINE DISTEMPER VIRUS 
1.4.1 History of Canine distemper virus 
Distemper is not a very precise description of a disease entity, however it has been applied for 
centuries for « that fatal disorder proper to the canine race called by excellence, the 
distemper ». Beside rabies, canine distemper (CD) is the only viral disease in dogs with a high 
mortality rate. It has a worldwide distribution and made its first appearance in Europe in 
Spain in 1761, introduced from either Asia or Peru. From Spain, it spread to all European 
countries within the same century and its first accurate description was made in 1809 by 
Jenner. In 1905, Carré reported that CD was caused by a virus and since then it is known as 
Carré’s disease (5). 
CD is an acute or subacute contagious febrile disease with nasal and ocular discharge, 
gastrointestinal and respiratory signs and leukopenia. A certain proportion of affected animals 
develop nervous manifestations, which may occur during the acute phase of the disease or 
several weeks or even months later. Hyperkeratosis of footpads is seen in some dogs. Many 
different species in the Order Carnivora are susceptible to CD and the mortality rate varies 
greatly between species. There have been several outbreaks of CD among lions of the 
Serengeti, lions, tigers, leopards in American zoos and seals. 
 
1.4.2 Canine distemper virus infection 
The original studies on the pathogenesis of distemper were conducted by Appel and 
coworkers (6, 7). Canine distemper virus (CDV) is generally transmitted as an aerosol 
infection to the upper respiratory tract. The primary virus replication takes place in the 
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lymphoid tissues. Infection of these tissues is associated with severe long lasting 
immunosuppression (126, 127). At about ten days post infection (p.i.), CDV starts to spread 
from the sites of primary replication to various epithelial tissues and to the central nervous 
system (CNS). The exact mechanism of entry of CDV in the CNS has not yet been clarified. 
However, one study describes the presence of CDV infected lymphocytes in the perivascular 
spaces of the CNS at ten days p.i (207, 208). The frequent occurrence of periventricular and 
subpial lesions and the fact that CDV can easily be found in choroids plexus cells and 
ependyma suggest entry of the virus in the brain tissue by way of the cerebrospinal fluid 
(CSF) pathways, presumably by infected immune cells. In the CSF, virus can be found in 
mononuclear cells. Such infected mononuclear cells have been found to be fused with 
ependymal cells (106). 
 
1.4.3 Neuropathology of canine distemper virus 
Although the spectrum of the lesions appear to be wide, the neuropathology of spontaneous 
distemper is remarkably constant. The variability of the lesions is largely due to their 
evolution when the disease progresses. Some variability may be due to strain differences, 
although there is little concrete evidence that these play a role in the natural disease in dogs. 
The polioencephalitis caused by the Snyder Hill CDV strain (206) does not appear to occur in 
nature. The so-called “old dog encephalitis” (135, 136), a disease which differs from the 
chronic form of common nervous distemper and closely mimics measles virus-induced 
subacute sclerosing panencephalitis (SSPE) in people, is exceedingly rare. In the vast majority 
of spontaneous distemper as well as in experimental studies with so-called “demyelinating” 
strains such as R252 (145) and A75/17 CDV (207), the virus causes multifocal lesions in the 
grey as well as in the white matter of the CNS. 
In the grey matter, CDV infects neurons, which can lead to neuronal necrosis and even 
polioencephalomalacia. Neuronal infection can also be widespread with remarkably little 
evidence of cytolysis. The white matter lesions in distemper are characterized by selective 
loss of myelin sheaths. These demyelinating lesions are not only responsible for severe 
neurological signs but are also thought to be a model for human demyelinating conditions 
such as multiple sclerosis (8). Therefore, the pathogenesis of demyelination has been closely 
investigated. 
Pathogenetic studies have to consider an acute and a chronic stage in the development of 
CDV-induced demyelination. The initial demyelinating lesions occur around 3 weeks p.i and 
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evolve during a period of massive immunosuppression, thus in the absence of any local 
inflammatory immune response. Depending on the degree and speed of immune recovery, 
animals may either become quickly moribund or may recover after developing a mild or even 
subclinical illness. An intermediary group of animals recovers slowly or partially and tends to 
develop a chronic or even relapsing disease with progression of the demyelinating lesions as a 
result of immunopathological reactions (225). 
 
1.4.3.1 The acute demyelination 
The initial demyelinating lesion develops during a period of severe immunosuppression and is 
not inflammatory (224). It is directly virus induced, since there is a clear correlation between 
the occurrence of demyelination and CDV replication in the glial cells of the white matter 
(227, 238). Demyelination is characterized by ballooning of myelin sheaths, phagocytosis and 
loss of myelin. The myelin is produced and maintained in the CNS by the oligodendrocytes. 
The obvious explanation for the phenomenon of demyelination would be infection of 
oligodendrocytes, the myelin producing cells. However, oligodendrocyte infection is a very 
rare event with an obvious lack of viral protein production in these cells (239, 241). The 
majority of infected cells are astrocytes (156), which are important for tissue homeostasis. 
Alteration of this cell population may, therefore, contribute to the development of 
demyelination. Release of potentially harmful products by other infected cells such as 
macrophages and lymphocytes leading to secondary damage of oligodendrocytes may also 
contribute to the demyelinating process. However, acute inflammatory infiltration is lacking 
in the earliest distemper lesions. 
The restricted infection of oligodendrocytes leads to a down-regulation of myelin gene 
transcription in oligodendrocytes (90) and reduced oligodendrocyte-specific enzyme activity 
(86). The down-regulation was detected already before demyelination occured and a decrease 
in the number of oligodendrocytes was not observed until demyelination became evident 
(189). 
 
1.4.3.2 The chronic demyelination 
The chronic disease in the surviving dogs is characterized by an influx of inflammatory cells 
in the initially virus-induced white matter lesions. These cells consist of lymphocytes, plasma 
cells and monocytes/macrophages, which accumulate around the blood vessels in the 
 22
meninges and also invade the parenchyma. The inflammatory lesions in chronic distemper are 
worse than the original acute virus-induced ones. The inflammatory reaction in distemper is 
associated with clearance of CDV from the lesions and correlated with the appearance of 
intrathecal produced neutralizing anti-CDV antibodies (25). However, CDV manages to 
persist in the CNS despite the presence of a vigorous antiviral immune response. 
Inflammation in chronic canine distemper causes progression of the demyelinating lesions, 
perhaps as a result of a bystander mechanism. The antiviral immune response may be 
responsible for such bystander degeneration of the white matter since anti-CDV antibodies 
binding to the surface of persistently CDV-infected brain cells stimulate macrophages to 
release reactive oxygen species (32), known to be toxic for many biological structures 
including myelin and oligodendrocytes (92). Oligodendrocytes are more vulnerable than other 
cells perhaps because they possess large amounts of lipid membranes and contain iron 
compounds important in the catalytic conversion of superoxide anion into the highly toxic 
hydroxyl radical. It is clear that macrophage activity primarily results in destruction of virus-
infected cells, and hence, is beneficial to the host, despite some degree of bystander damage 
to non-infected cells (26). However, if such reactions are maintained because of continuous 
viral antigen presence, the antiviral defence becomes detrimental to the host. Therefore, virus 
persistence is probably the key to antiviral immune response-mediated demyelination. 
The key role of macrophages in distemper pathogenesis may be somewhat surprising in view 
of the fact that CDV has a very strong tropism for these cells. Moreover, the CDV-infection 
of macrophages tends to enhance their destructive potential (29). 
The antiviral immune response seems to be effective in that CDV is removed from the 
inflammatory lesions, at the cost of some tissues. It is possible that a dog may recover perhaps 
with some residual signs, but the experience has shown that a progressive course is the rule in 
distemper. The continuous presence of the virus provokes a continuous antiviral immune 
response and therefore progression of tissue damage. 
Viral persistence in the CNS is the driving force behind the chronic progressive disease 
caused by natural CDV infection in dogs. Viral persistence is multifactorial and depends on 
properties of the host but also on viral factors. Persistence of CDV is associated with non-
cytolytic spread and impaired viral budding (236, 237) as well as with a restricted infection of 
certain cells with reduced viral protein expression (154). As a result of the antiviral immune 
response, the surface proteins of the virus could be modified in such a way that the virus is no 
longer detected by the immune system or that incomplete viruses are produced (2).   
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1.5 ADAPTATION OF VIRUSES 
Adaptation refers to a character that arises via natural selection and thus confers the ability to 
succeed genetically in a specific environment. Adaptations are therefore an evolutionary 
response to selective pressure presented in the form of environmental conditions that affect 
reproductive output. Selective pressures are directly related to survival and replication within 
a host and transmission between hosts. 
Selection arising from direct competition between virus strains for access to reproductive 
resources often ends up with the displacement of one population by the other. In contrast, 
when two populations exist in direct competition for some resource, the processes of 
adaptation and counteradaptation must be continually occurring for both populations to 
survive. Such adaptation within natural host populations is more difficult to confirm and has 
even been discounted for some mammalian RNA viruses (182). 
Certain adaptations may permit entry into an unusual reproductive environment. The result 
will be a new population perhaps exhibiting a different reproductive lifestyle. This is often the 
case when viruses cross tissue, host, or vector species barriers. This could occur by the change 
of single amino acids in a specific gene enabling the virus to replicate in different cell types. 
These minor changes represent a recently acquired adaptation that allowed replication in a 
new, susceptible host species. 
The presence of genetic variation does not ensure evolutionary change. Such change is 
dependent on the existence of some degree of either directional or diversifying selective 
pressure. Stabilizing selection, on the other hand, may result in long periods of little to no 
evolutionary change and can, when strong enough, cause tremendous genetic homogeneity 
among individuals in a population despite high rates of mutation or genetic exchange. 
Ecology is a science that investigates the interactions between an organism and its 
environment. Environment refers to the physical, biological, and stochastic elements that 
constitute the habitat that allows an organism to reproduce at a given time. The environment 
thus uniquely determines the type and degree of natural selective pressure exerted on a 
population. Viruses have both general and specific requirements for replication and existence. 
All viruses require the use of a host cell’s adenosine triphosphate (ATP), ribosome, 
nucleotide, transfer RNA, and amino acid resources. Many viruses also require use of other 
cell functions and components, such as replication and splicing machinery. Often, viruses use 
more advanced host characteristics, especially when dealing with the demands of 
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transmission. Here, they may take advantage of host ecology, feeding habits, sexual behavior, 
social structure, and so forth to facilitate host-host transfer. 
Although viruses as a group are presumably capable of using any cellular organism for 
replication, individual virus types are usually specialized in the host species they parasite. The 
specific set and degree of environmental conditions within which an individual (e.g virus 
type, species) is adapted for survival and reproduction is referred to as an ecological niche. 
The ecological niche is unique to a particular life form and thus should be considered as a 
characteristic of that life form. However, the ecological niche of a virus is not fixed and 
evolves just as any other viral trait or phenotype. 
Most viruses exist with two main reproductive objectives: survival and replication within host 
cells and successful transmission of progeny to new host cells for subsequent survival and 
reproduction. This translates into distinct environments in which viruses must exist, that is, 
the intra- (within) host and inter- (between) host. 
The intrahost environment consists of the replicative resources and conditions to which a 
virus is exposed both within the host organism (extracellular) and within the host cell 
(intracellular). This environment contains two primary forces that exert evolutionary pressure 
on infecting viruses: first, competition between individual viruses for intrahost resources, and 
second, the antiviral defense mechanisms exhibited by the infected host. 
Concerning the interhost environment, it has been demonstrated that to persist evolutionary a 
virus must give rise to progeny that successfully infect at least one new host organism of the 
same or different species, To infect a new host, two principal conditions must be met. First, 
new, susceptible hosts must exist, usually within a limited spatial scale. Second, viruses must 
have access to a vehicle or pathway of safe transport to a new host. The interhost environment 
thus includes all the conditions to which a virus is exposed when it is not occupying a host 
organism. 
 
Adaptation of a virus to non-natural host cells is often accompanied by the attenuation of the 
virulence in the natural host animals, as has been reported with many viruses such as 
influenza virus (28), Japanese encephalitis virus (34), hepatitis A virus (91), Borna disease 
virus (91), human immunodeficiency virus (74, 183). The mechanisms of attenuation / 
adaptation have been intensively studied to make use of them for designing new vaccines. 
Sequence comparisons of the wild-type and cell-adapted variants can provide useful markers 
associated with virus pathogenicity and host restriction. The observed mutations have then to 
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be well studied and have to be distinguished between important functional mutations and 
those representing quasispecies, thus occupying only a minor portion of the genetic swarm. 
For many RNA viruses, the answer to the importance of mutations was found from the fruitful 
field of reverse genetics.  
 
Cell culture adaptation of paramyxoviruses is frequently associated with changes in the 
attachment proteins (179), enabling the virus to enter cells via alternative receptors (142). 
Another mechanism of adaptation involves mutations in the P/V/C and L genes suggesting the 
importance of amino acid changes in the polymerase and accessory proteins for the MV 
attenuation and cell tropism (211, 215).  
Adaptation of A75/17 CDV in Vero cells involved only seven mutations in the P/V/C, M and 
L genes but none in the F and H genes, changing the amino acid sequences of the P, V, M and 
L proteins, but not of the C protein (170). In addition, no change was revealed in the cis-
acting regulatory regions for viral transcription and replication, including the leader, trailer, 
stop-restart, and intergenic sequences. Moreover, no change was found in the non coding 
regions of all six CDV genes, which might be involved in translational regulation. Thus, the 
identified nucleotide changes were all within the ORFs and resulted in amino acid changes. 
The sequence data was therefore highly informative in that the phenotypic differences both in 
vitro and in vivo between the two virus strains were attributable to the changes in viral 
proteins. All these mutations will be extensively studied in this thesis and will maybe give 
intersting clues to the pathogenicity of canine distemper virus. 
 
1.6 THE SIGNALLING LYMPHOCYTE ACTIVATING MOLECULE (SLAM) 
1.6.1 Structure and function of CD150 (SLAM) 
SLAM (CD150) is classified as a member of the CD2 family. The CD2 family of receptors is 
part of the immunoglobulin (Ig) superfamily, which includes 11 cell surface molecules. The 
characteristic signature of the CD2 family is within the extracellular region: an N-terminal 
variable (V) Ig domain lacking disulfide bonds is followed by a truncated Ig constant 2 (C2) 
domain with two intradomain disulfide bonds. All CD2 family members are glycoproteins 
with extracellular N-linked glycosylation sites, but no putative O-glycosylation sites.  
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The CD150 subfamily contains six known members named SLAM (CD150), 2B4 (CD244), 
CD84, CS1 and NTB-A (or Ly-108), which presents the similar structure. SLAM is a type I 
transmembrane protein. In its cytoplasmic tail are three unique immunoreceptor tyrosine-
based signaling motifs (ITSMs) with the consensus sequence TxYxxV/I/A. Alternate splicing 
produces a soluble form lacking the transmembrane domain and a variant membrane form 
lacking the two distal ITSMs in the cytoplasmic tail, whose forms are currently of no 
relevance in vivo.  
SLAM has been discovered in humans, mice, dogs, cattles and marmosets, but the tissue 
distribution and function have been thus far studied only for human and murine SLAMs. 
SLAM is constitutively expressed on immature thymocytes, CD45Rohigh memory T cells, and 
a proportion of B cells and is rapidly induced on peripheral T and B cells following 
activation. It is not detected on immature dendritic cells, granulocytes, monocytes, red blood 
cell, or platelets. However, it is induced on mature dendritic cells after activation with CD40L 
or IL-1β (22) and on monocytes after activation with LPS or TNF-α (232). 
SLAM is homophilic and is thought to function through bidirectional signalling after SLAM-
SLAM associations. In T cells, it leads to IL-2 independent expansion and IFN-γ production 
(10, 44), whereas in B cells, it induces proliferation (195), antibody production (174) as well 
as CD95-mediated apoptosis (150). Thus, SLAM appears to mediate context-dependent 
functions in lymphocytes. 
 
1.6.2 The signalling of SLAM receptor 
The signalling pathway of SLAM begins with the binding of the SLAM-associated protein 
(SAP) to the immunoreceptor tyrosine-based signaling motifs (ITSMs). SAP competitively 
inhibits recruitment of the protein tyrosine phosphatase SHP-2 and facilitates the recruitment 
of the FynT tyrosine kinase to the phosphorylated  cytoplasmic domain of SLAM. This 
promotes the phosphorylation of several downstream intermediates and delivers an inhibitory 
signal associated with the selective attenuation of IFN-γ secretion by activated T 
lymphocytes. In cells that lack expression of SAP, ligation of SLAM does not induce the 
phosphorylation of SLAM, which indicates that SAP is required to deliver a SLAM-mediated 
phosphorylation signal. 
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1.6.3 The Morbillivirus receptor SLAM 
Recently, Tatsuo et al (2000) have reported that human SLAM is a cellular receptor for 
measles virus (218). Since the tissue distribution of human SLAM can explain the pathology 
of measles, they proposed that selective infection and destruction of SLAM-positive cells may 
be a principal mechanism of the immunosuppressive nature of morbilliviruses in general. The 
use of canine and bovine SLAM receptors has also been demonstrated for CDV and 
rinderpest viruses, respectively (219). Despite sequence differences, the structure required for 
the interaction with morbillivirus H proteins may be well conserved among SLAMs of many 
different species. 
The use of SLAM as a receptor may be a property common to most, if not all, of the members 
of morbilliviruses. SLAM is selectively expressed on the cells of the immune system and the 
destruction and/or impairment of infected SLAM-positive cells may be a mechanism for the 
immunosuppression induced by morbilliviruses, but other mechanisms may be involved. 
 
1.7 CANINE DISTEMPER VIRUS STRAINS 
There exists different strains of canine distemper virus including three virulent strains known 
as Snyder Hill, Ohio R252 and Cornell A75/17 and one vaccine strain called the 
Onderstepoort strain.  
The Snyder Hill strain (SH) causes an acute encephalomyelitis with predominantly gray-
matter changes, whereas strains Ohio R252 and Cornell A75/17 cause delayed 
encephalomyelitis with predominantly white-matter lesions and demyelinating reminiscent of 
CNS lesions in multiple sclerosis. In addition, strain R252 and A75/17 may induce persistent 
infection without clinical signs. Thus, the outcome of infection depends upon both viral and 
host factors. 
As the virulent strains are difficult to study in vitro due to their inefficient multiplication in 
cultured cell lines, the virulent A75/17 has been adapted first to Vero cells and later also to 
primary dog footpad keratinocytes. 
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1.7.1 The wild-type A75/17 strain 
The wild-type Cornell A75/17 CDV strain may be considered as the prototype virulent CDV 
and causes distemper in dogs and other carnivores (9, 167). A75/17 CDV readily replicates in 
dog or ferret macrophages (29, 148, 149) as well as in primary dog brain cell cultures 
(DBCC) (240). In DBCC, the virus produces a noncytolytic, persistent infection with very 
selective virus spread via microfusions between cell processes (236), characteristic of the in 
vivo situation in the central nervous system (227).  
In contrast, A75/17 CDV does not replicate in any cell line so far tested, including not only 
cultured cell lines like Vero, CHO, BHK and 293T7 cells, but also in specific cell lines like 
dog macrophages and dog thymus. The identification of the cellular SLAM receptor by 
Tatsuo and colleagues in 2000 as the first in vivo cell surface molecule used by wild-type 
morbillivirus strains allowed multiplication of A75/17 in cultured cell lines transfected with 
this receptor. These infections are characterized by the formation of multinucleated cells 
known as syncytia and are representative of the in vivo situation in the lymphoid cells and 
organs. However, it does not reflect the situation in the central nervous system, where SLAM 
is not expressed. 
 
1.7.2 The adapted A75/17-V strain 
In 1991, Hamburger and colleagues passaged the wild-type A75/17 CDV strain in Vero cells 
and obtained after 17 successive blind passages the adapted A75/17-V CDV strain (98). No 
infected Vero cells could be detected until passage 12 and the virus stock used for 
experimental studies was passage 17. This adapted virus acquired the capacity to multiply in 
Vero cells by entering Vero cells through a yet unidentified CDV receptor. The exact 
mechanism of this adaptation is unknown and has been determined in this thesis project. 
Sequencing of both CDV strains highlighted only seven mutations in the P/V/C, M and L 
genes, which induced amino acid changes in the P, V, M and L proteins, but not in the C 
protein. No differences were observed in the genes encoding the surface glycoproteins (170). 
The adapted virus has been shown to induce persistent infections of cultured cell lines without 
any obvious presence of syncytia. In the presence of the SLAM receptor, it also produced 
syncytia. Interestingly, upon cell culture adaptation, this virus does not enter the central 
nervous system any more thus showing attenuation in vivo. This has been tested in only two 
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experimental dogs and needs to be confirmed (98). However, this virus may be interesting for 
studying the molecular mechanisms of CDV pathogenesis. 
 
1.7.3 The vaccine strains 
In 1958, a virulent CDV strain was propagated in primary dog kidney cells and gave rise to 
the virus strain named Rockborn-CDV. This virus was used for vaccination of dogs, but still 
remained virulent in ferrets. In addition, recovery of virulence has been observed in some 
cases of vaccinated dogs. This strain was poorly studied and has been replaced by the 
Onderstepoort strain for vaccination. 
The Onderstepoort strain (OP-CDV) has been passaged several times in embryonated chicken 
eggs, then amplified in many different cell lines such as monkey kidney Vero cells. It is used 
for vaccination of dogs and ferrets and no virulence recovery has been observed until now in 
the vaccinated dogs in contrast to the Rockborn-CDV strain. The main characteristic of the 
OP-CDV strain is its cytolytic effect observed in any cell lines so far tested. It induces the 
formation of large syncytia leading to the complete destruction of the cell monolayer. This 
has been observed in the absence and in the presence of the SLAM receptor without any 
visible differences between the two suggesting a weaker affinity of the OP-CDV strain for 
this receptor as compared to the wild-type strain. 
 
1.8 REVERSE GENETICS 
The study of viruses and their interactions with host cells and organisms has benefited greatly 
from the ability to engineer specific mutations into viral genomes, a technique known as 
reverse genetics. 
Genetic manipulation of RNA viruses requires the ability to recover the virus from a DNA 
copy of the RNA genome. This became feasible early with positive-strand viruses where the 
genomic RNA itself, or a corresponding DNA-derived transcript, acts as a mRNA and is 
infectious after introduction into a suitable host cell. The genomes of negative-strand RNA 
viruses have been less amenable to manipulation for several reasons: (i) precise 5’ and 3’ ends 
are required for replication and packaging of the genomic RNA; (ii) the viral RNA 
polymerase is essential for transcribing both mRNA and complementary, positive-sense 
antigenome template RNA; and (iii) both genomic and antigenomic RNAs exist as viral 
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ribonucleoprotein (RNP) complexes. The minimum infectious unit of negative-strand RNA 
viruses is the ribonucleocapsid (RNP) complex. Therefore, all efforts toward manipulation of 
negative-strand RNA viruses were directed toward assembly of RNA into RNP-like structures 
(review). 
The initial breakthrough came with the description by Palese and colleagues of a system that 
allowed generation of biologically active Influenza A virus RNPs containing artificial RNA 
(139). Transcripts generated in vitro possessing authentic terminal sequences from an 
influenza genome segment and containing an internal CAT reporter gene were encapsidated 
in vitro by purified influenza virus nucleoprotein and the viral polymerase proteins (PA, PB1, 
and PB2). After transfection of the reconstituted RNP into virus-infected cells, the construct 
was replicated and transcribed and this system has since been extremely useful for the 
analysis of influenza virus. Although the segmented genomes of influenza viruses, 
bunyaviruses, and arenaviruses allowed some genetic manipulations through the isolation of 
reassortant viruses, manipulation of the complete genome of segmented negative-strand RNA 
viruses has progressed slowly, hampered by the fact that the genome is segmented. 
 
1.8.1 The nonsegmented negative-strand RNA viruses 
The first complete infectious nonsegmented negative-strand RNA virus was recovered in 
1994 for rabies virus (188). The key to reproducibly recovering recombinant virus was the use 
of a plasmid directing transcription of antigenome (positive-strand) RNA, rather than genome 
RNA. The use of positive-sense RNA turned out to be successful for other nonsegmented 
negative-strand RNA viruses, and established systems for recovering members from all 
rhabdovirus (rabies and VSV) and paramyxovirus genera are now available. If naked 
negative-strand RNA genomes are produced in the cytoplasm of cells that are also producing 
complementary mRNAs encoding viral proteins, the two can hybridize and prevent the 
critical assembly of the genome into the RNP. In starting with an antigenome RNP, only one 
successful round of replication driven by the plasmid-encoded support proteins is required to 
yield an infectious genome RNP. Nagai et al reported that recovery of Sendai virus with a 
negative-strand construct was 100-fold lower than with a positive-strand (121). 
In the Morbillivirus genus, measles virus has been the first to be recovered in 1995 (177), 
followed by Rinderpest virus in 1997 (15). The first for measles virus was the Edmonston B 
vaccine strain carrying two tags in the untranslated regions between the N and P reading 
frames. Then the highly pathogenic IC-B strain was also rescued (212). For canine distemper 
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virus, the vaccine strain has only been rescued from a full-length cDNA clone in 2000, using 
the MVA-T7-based system (82). 
The possibility of genetically manipulating negative-strand RNA viruses opens the way to 
study virus biology and virus-host interaction. Any mutation, including those studied 
previously, can now be examined in the most relevant and important context, the virus’ life 
cycle. Analysis of numerous mutations with the infectious clones will probably also identify 
mutations that attenuate the viruses and that could be used to develop new vaccine strains. In 
addition, nonsegmented negative-strand RNA viruses have an exciting potential as vector to 
express foreign genes.  
 
1.9 THESIS PROJECT 
The wild-type A75/17 CDV virus is responsible for the neuropathological disease of canine 
distemper virus. In order develop a treatment, this virus has to be well understood. As 
experimental infections of the dog are very difficult to perform, this virus needs to be 
characterized first in vitro for subsequent study in vivo. Unfortunately, this virus does not 
grow in any cell line so far tested and is thus very difficult to study. For that reason, 
Hamburger and colleagues have adapted this virus in Vero cells, a monkey kidney-derived 
cell line in 1991. This new virus strain was obtained after 17 blind passages of the virulent 
strain and is now able to grow efficiently in Vero cells. 
In our laboratory, both virus strains have been sequenced and only seven nucleotide changes 
were found, all changing amino acids. Three mutations were found in the P gene, changing 
both the P and V proteins, but not the C protein, three mutations in the M gene and one 
mutation in the L gene, as described by Plattet and colleagues (170). These mutations induced 
not only a phenotypic change in cultured cell line, but also a pathologic difference, in that the 
adapted virus could not enter the central nervous system of the dog any more. 
In order to better understand the disease in the dog, comparative studies with the virulent and 
the adapted viruses are crucial to dissect the adaptation process and the implication of the 
different mutations in pathogenicity. 
The majority of the mutations affected the RNA dependent RNA polymerase (RdRp) of 
canine distemper virus, constituted of the P and L proteins. This polymerase was assumed to 
play an important role in the adaptation process and was thus the basis of this thesis project.  
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In the way of understanding how the wild-type virus could be adapted to a cell line, which is 
non permissive, it was presumed that there was a block either at the entry step or once in the 
cell, at the multiplication step. The first evidence for the entry of the virus in Vero cells was 
the adaptation itself, in which the virus has to enter once in the cell and to mutate under 
selective pressure. 
Taken this hypothesis into account, the block of the wild-type virus was expected to be at the 
level of the replication of the virus itself, which could be explained by a difference in the 
polymerase activity of both virus strains. This was supported by many published studies, 
which showed that adaptation of a virus in Vero as well as other cell lines leads to an 
attenuation. This attenuation was often associated with mutations in the P and L genes 
resulting in changes in the transcription and replication activities. 
In addition, it is well known that the polymerase activity can be regulated by other viral 
proteins as well as by cellular proteins. The M protein has been reported to inhibit viral 
transcription for many different viruses and will be considered in this thesis project. The 
accessory V and C proteins will also be studied with respect to their role in polymerase 
activity and in the pathogenesis of these two virus strains. 
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2. MATERIAL AND METHODS 
2.1 CELLS  
The monkey kidney-derived Vero cell line was grown in DMEM supplemented with 10 % 
heat-inactivated FBS and 1% antibiotics at 37 °C. The chinese hamster ovarian-derived 
CHO/DG44 (ATCC) cell line was grown in DMEM/NUT.MIX.F-12 (Gibco) supplemented 
with 10 % FBS and 1x hypoxanthine (Gibco).  The CHODogSLAM cell line stably 
expressing the dog SLAM receptor was grown in DMEM/NUT.MIX.F-12 supplemented with 
10 % FBS, 1x hypoxanthine and 0.5 mg ml-1 geneticin. The hamster kidney-derived BSRT7/5 
cell line stably expressing the T7 RNA polymerase was grown in DMEM supplemented with 
10 % heat-inactivated FBS, 1 % antibiotics and 0.4 mg ml-1 geneticin (31). 
 
2.2 ESTABLISHMENT OF CHODOGSLAM CELLS 
The plasmid pCAGDogSLAMtag, from which canine SLAM is expressed as a fusion protein 
with the influenza virus HA tag at the N terminus (159, 219) was used for the establishment 
of a stable cell line. The pCAGDogSLAMtag plasmid, together with a neo encoding plasmid 
was transfected in CHO/DG44 cells (ATCC) and clones were selected in the presence of 
G418, followed by immunofluorescence staining with anti-HA epitope mAb. The cells 
expressing the highest level of canine SLAM, designated CHODogSLAM cells, were used in 
the following experiments. 
 
2.3 VIRUSES  
The A75/17 wild-type canine distemper virus strain was obtained from M. Appel, Cornell 
University, Ithaca, N-Y (9) and grown in experimentally infected dogs. A homogenate of 
lymphoid organs was used for infection of Vero and CHODogSLAM cells. The Vero cell-
adapted CDV, designated A75/17-V, was obtained after 17 blind passages of the wild-type 
virus in Vero cells (98). Virus stocks were made by 3 cycles of freeze and thaw of infected 
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Vero cells. After centrifugation, the supernatant was used for infection experiments. Modified 
vaccinia virus Ankara (MVA) expressing the T7 RNA polymerase was used for infection at a 
m.o.i. of 1.5 (67). 
 
2.4 TITRATION OF VIRUSES AND INFECTION 
Titration of A75/17 and A75/17-V CDV was performed by limiting dilution in 
CHODogSLAM cells. Cells were infected for 24 h with different dilutions of both viruses. 
After staining by immunocytochemistry, single infected cells for A75/17-V and syncytia for 
A75/17 were counted.  
Cells were infected at a confluence of 50% with A75/17 or A75/17-V CDV at a m.o.i. of 
0.0001. After 1 h at 37 °C the virus suspension was removed and the cells were incubated for 
different time points in medium containing 2 % FBS.  
 
2.5 CONSTRUCTION OF PLASMIDS 
The minireplicon plasmids, designated pCAT(-) and peGFP/CAT(+), containing the CAT 
gene in genome orientation and the eGFP and the CAT genes in anti-genome orientation, 
respectively, were constructed using standard methods (143). The reporter genes are flanked 
in 5’ by the CDV genome promoter and in 3’ by the CDV anti-genome promoter, 
corresponding to the so called minireplicons. In the peGFP/CAT(+), the eGFP and the CAT 
genes are separated by a synthetic non-coding region composed of the end sequence of the N-
P genes and the I-S of the N gene (NCR N-P-N). The minireplicon eGFP/CAT (+) is under a 
T7 promoter at the 5' end and a T7 terminator downstream of the hepatitis delta virus 
ribozyme sequence (193) at the 3' end. On the opposite, the minireplicon CAT (-) was 
constructed with a T7 promoter at the 3’end  and a T7 terminator downstream the hepatitis 
delta virus ribozyme sequence at the 5’ end. 
The genes encoding the N, P, C, V, M and L proteins of A75/17 and A75/17-V CDV were 
cloned into the NcoI site, providing the AUG translation initiation codon, and the XhoI site of 
the pTM-1 vector. In this vector, the genes are expressed under the control of the T7 promoter 
and the resulting RNA has an IRES sequence allowing internal ribosome entry. The sequence 
of the cloned P, V, M and L genes of A75/17-V CDV was changed into the sequence of 
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A75/17 CDV by site directed mutagenesis using the Quick Change Site Directed Mutagenesis 
kit (Stratagene). These plasmids were designated pTM-N, pTM-P A75/17, pTM-P A75/17-V, 
pTM-V A75/17, pTM-V A75/17-V, pTM-M A75/17, pTM-M A75/17-V, pTM-L A75/17 and 
pTM-L A75/17-V.  
The expression of the C protein was abrogated in the pTM-P and the pTM-V expression 
plasmids by mutating the AUG C start codon in an ACG and by introducing a stop codon 14 
nt downstream without changing the P and the V ORFs. This was done by site directed 
mutagenesis. 
The beta-galactosidase (β-gal) gene was cloned in a plasmid under the control of a CMV 
promoter and was designated pCMV-β-gal. 
 
2.6 MINIREPLICON ASSAY 
Vero and CHODogSLAM cells, in 6-well culture dishes at a confluence of 100 %, were first 
infected with MVA at a m.o.i. of 1.5 at room temperature for 1 h, and then transfected with 
Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer’s protocol. The 
following plasmid concentrations were used for transfection: 300 ng of pCAT(-) or 
peGFP/CAT(+), 100 ng of pTM-N, 100ng of pTM-P or pTM-P/C-, 25ng of pTM-L, 50ng of 
pTM-V, 50-100ng of pTM-M and 150ng of pCMV-β−gal.  
After 4 h, the medium was replaced by medium containing 10 % FBS. At 24 h after 
transfection, the cells were lysed with 0.5 ml of lysis buffer contained in the CAT ELISA kit 
(Roche). 
 
2.7 MEASUREMENT OF CHLORAMPHENICOL ACETYL TRANSFERASE (CAT) AND 
β−GALACTOSIDASE  
Cell lysates were diluted 10-fold and assayed for the presence of CAT and β-galactosidase. 
The β-galactosidase measurement was performed at 595 nm using 30 µl of cell lysates, which 
was mixed with 150 µl of CPRG buffer (60 mM Na2HPO4 7.H2O, 40 mM NaH2PO4, 10 mM 
KCL, 1 mM MgSO4, 50 mM ß-mercaptoethanol) and 20 µl of CPRG diluted at 4mg ml-1 in 
H2O. An ELISA kit (Roche) was employed for CAT quantification according to the 
 36
manufacturer’s instructions using 200 µl of cell lysates. Absorbances were read at 405nm and 
normalized to the values of β−galactosidase. The normalized results were expressed as CAT 
concentration determined from a standard curve. 
 
2.8 WESTERN BLOTTING 
Total proteins from cell lysates were quantified using the Bio-Rad Protein Assay based on the 
Bradford’s principle. The protein concentrations were determined at 595nm using a standard 
curve of increasing amounts of bovine serum albumine (BSA). Proteins were loaded on SDS-
PAGE using 30% acrylamide stock (29:1, Bio-Rad) and Western blotting was performed with 
different antibodies: D110 anti-N mAb (98), anti-β−tubuline mAb, anti-P 4.415 mAb (144), 
anti-L rabbit antiserum, X1-6 anti-M mAb. 
 
2.9 IMMUNOCYTOCHEMISTRY 
Cells were fixed with ethanol:acetic acid (95:5) and blocked with 5% goat serum. Viral 
antigen was demonstrated using the D110 anti-N mAb (98) and the unlabelled antibody 
peroxidase-antiperoxidase (PAP) method (204).  
 
2.10 RNA EXTRACTION 
Total RNA from animal cells grown in a monolayer was extracted either by the Trizol 
method (Gibco) or by the RNeasy Mini kit (Qiagen) according to the manufacturer’s 
instructions directly in a 6-well culture dish. 
 
2.11 RNASE PROTECTION ASSAY (RPA) 
The specific probe of 323 nt was designed in the peGFP/CAT(+) as a DNA fragment 
spanning 44 nt of the eGFP gene, the intergenic region (66 nt) and 213 nt of the CAT gene. It 
was subcloned in the pGEM-TEasy Vector (Promega) in the anti-sense orientation 
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(pGEMGFPCAT). The internal L27 probe was cloned in a pBluescript vector (pBSL27). The 
plasmids were digested by SpeI and EcoRI respectively and transcribed in vitro in the 
presence of [32P] UTP (ratio 1:0 of hot:cold UTP) according to the MAXIscript kit 
(Ambion) instructions. The labelled probes were diluted to 8x104 cpm ml-1 for the GFPCAT 
probe and to 6x104 cpm ml-1 for the L27 probe, then hybridized to total RNA following the 
Direct Protect kit instructions (Ambion). Digested products were resolved in a denaturing 
6% polyacrylamide gel containing 8M Urea. Electrophoresis was performed for 5 h at 2000 
V, the gel was dried under vacuum and exposed to X-Ray film. 
 
2.12 MICROCOCCAL NUCLEASE (MNASE) TREATMENT AND RT-PCR 
Vero cells were lysed with 100 µl of lysis buffer (69). Thirty units (U) of Micrococcal 
nuclease S7 (Amersham) was added to one half of the cell lysate, while the other half was left 
untreated. Samples were incubated at 30°C for 1 h. Total RNA was then extracted by the 
Trizol method and submitted to RT-PCR. Reverse transcription was performed with the 
Omniscript RT kit (Qiagen) with the primer RNA leader (5’ 
TTTAATAACTTATAAAATAATTTTTG 3’). The cDNA was amplified with Taq 
polymerase using the CAT+ primer (5’-CGTTCAGCTGGATATTACG-3’) and CAT- primer 
(5’-AACTCACCCAGGGATTGCT-3’). The L27 gene was amplified with the L27+ primer 
(5’-CATCGTGAAGAACATTGACGATG-3’) and the L27- primer (5’-
CCCATGGCAGCTGTCACTTT-3’). 
 
2.13 GROWTH KINETICS  
To determine growth kinetics, the supernatant of infected cells was collected and stored at –
70 °C. Cell-associated viruses were released by 2 cycles of freeze and thaw, cell debris were 
removed by centrifugation at 3000 rpm for 8 min at 4°C and the supernatant was stored at-70 
°C. For titration, supernatant and cell-associated viruses were thawed and different dilutions 
were used to infect CHODogSLAM cells. After 24 hours, infected cells were detected by 
immunocytochemistry. 
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2.14 GENERATION OF RECOMBINANT CDV VIRUSES KNOCK-OUT FOR THE C 
PROTEIN 
The NruI restriction site in the full-length antigenome pA75/17-V2 (ref plattet) has been 
eliminated from the non coding region between the leader and the N gene (pA75/17-V3), 
which plasmid has been rescued and corresponded to the recombinant A75/17-V virus. This 
plasmid has then been modified in order to abrogate C protein expression from A75/17-V 
CDV. This was done by the mutation of the C AUG start codon into ACG and by the 
introduction of a stop codon some amino acids downstream without changing the P and V 
ORFs (pA75/17-V3 P/C-). These two plasmids were used for the rescue of A75/17-V and 
A75/17-V P/C- viruses. 
BSRT7/5 cells at a confluence of 50% were transfected with lipofectamine 2000 with the 
following plasmid: 1µg of either pA75/17-V3 or pA75/17-V3 P/C-, 200ng of pTM-N, 200ng 
of pTM P A75/17 and 50ng of pTM-L A75/17. After 2 days, the transfected cells were 
trypsinized and cocultured with fresh Vero cells at a confluence of 80%. After 3-5 days, the 
coculture was freezed and thawed twice and the supernatant was used to infect fresh Vero 
cells for 5 days at 37°C. Finally, cells were freezed and thawed twice and the supernatant was 
aliquoted and stored at –70°C. The presence of recombinant viruses was tested by 
immunocytochemistry on reinfected Vero cells. 
 
2.15 RADIOACTIVE LABELLING AND IMMUNOPRECIPITATION 
Cells were labelled with 100µCi of 35S-labelled methionine and cysteine mix (Redivue 
PRO-MIX, Amersham) for 4 hours at 37°C, washed with PBS and lysed with 1ml of TNE 
buffer (10mM Tris-HCl pH 7.4, 150mM NaCl, 0.5% NP-40 and 1mM EDTA). 
For immunopreciptation, cell lysates were incubated with a D110 anti-N mAb for 1 hour at 
4°C, then with Protein G Plus-Agarose beads (Santa Cruz Biotechnologies) O/N at 4°C. 
Complexes were loaded on a SDS-PAGE and detected either by Western blotting or by 
autoradiography. 
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Abstract  
Wild-type A75/17 Canine distemper virus (CDV) is a highly virulent strain, which induces in 
dogs a persistent infection in the central nervous system (CNS) with demyelinating disease. 
Wild-type A75/17-CDV, which is unable to replicate in cell lines to detectable levels, was 
adapted to grow in Vero cells and was designated A75/17-V. Sequence comparison between 
the two genomes revealed 7 nucleotide differences located in the phosphoprotein (P), the 
matrix (M) and the large (L) genes. The P gene is polycistronic and encodes besides the P 
protein the two auxiliary proteins V and C. The mutations resulted in amino acid changes in 
the P and V but not in the C protein, as well as in the M and L proteins. Here, a rescue system 
was developed for the A75/17-V strain, which was shown to be attenuated in vivo but which 
retains a persistent infection phenotype in Vero cells. In order to track the recombinant virus, 
an additional transcription unit coding for the enhanced green fluorescent protein (eGFP) was 
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inserted at the 3' proximal position in the A75/17-V cDNA clone. Reverse genetics 
technology will thus allow us to characterize for the first time the genetic determinants of 
A75/17-V CDV persistent infection in cell culture.  
Keywords: persistent canine distemper virus, Vero cell-adaptation, complete nucleotide 
sequence, reverse genetics, additional transcription unit 
 
Canine distemper virus (CDV), a member of the genus Morbillivirus of the family 
Paramyxoviridae, causes neurological symptoms by spreading in the central nervous system 
(CNS) of dogs and other carnivores (226). The A75/17 CDV strain typically produces a 
delayed, subacute to chronic, demyelinating CNS disease (166, 167). This highly virulent 
strain grows in primary dog brain cell cultures but is unable to replicate in cell lines to 
detectable levels (5, 226, 240). The CDV genome is 15690 nucleotides long and consists of 
six genes encoding the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), 
attachment (H) and large (L) proteins (17-19, 54, 146, 180, 194). The nonstructural proteins V 
and C are encoded within the P gene (20, 38).  
A Vero cell-adapted strain was obtained after 17 repeated passages of A75/17 CDV in Vero 
cells and was designated A75/17-V. This strain has a strongly reduced pathogenicity in dogs 
(98) but has retained the ability to cause a persistent infection in vitro (147). 
Recently, a reverse genetics system has been reported for the Onderstepoort CDV (OP-CDV) 
vaccine strain (82, 162, 230). However, OP-CDV has been passaged extensively in cell 
culture, is highly attenuated in the dog, produces a non-persistent, cytolytic infection in 
cultured cells (237), and is therefore phenotypically distinct from wild-type isolates.  
In this study, we report the complete nucleotide sequences of the A75/17 and A75/17-V 
genomes, as well as the successful recovery of the A75/17-V strain from cloned cDNA. 
Despite the screening of a large number of cell lines, we were unable to find one, in which the 
A75/17-V virus formed syncytia, precluding the isolation of cloned recombinant viruses. An 
additional transcription unit coding for the enhanced green fluorescent protein (eGFP) was 
therefore inserted in the A75/17-V genome. This strategy enabled us not only to clone 
recombinant persistent viruses but also to follow the infection in living cells by very sensitive 
means. Thus, reverse genetics technology based on the genetic lineage of the highly virulent 
A75/17 dog isolate should allow us to study the determinants of persistent infection and 
virulence in the natural host.  
To identify the changes that had occurred upon cell culture adaptation of the A75/17 virus, the 
genomes of the A75/17 and A75/17-V CDV were sequenced. cDNA was synthesized by RT-
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PCR using RNA isolated either from the thymus of A75/17 CDV infected dogs or from 
A75/17-V infected Vero cells. Purified PCR fragments were directly subjected to DNA 
sequencing. To sequence the 3’ and 5’ ends of the genome, cDNA of both termini were 
synthesized by the RACE method (116, 184, 229), using the GeneRacer Kit (Invitrogen, 
Carlsbad, CA), and cloned into the plasmid pUC18. Several clones were sequenced. 
Comparison of the two genomes revealed that the length of 15690 nucleotides and the overall 
organization were identical. Only 7 nucleotide differences were found. Three of these were 
located in the P/V/C gene, 3 in the M gene, and 1 in the L gene (Table 2). The other genome 
regions including the leader, trailer, transcription start and stop signals, intergenic sequences 
and non-coding regions of all six genes remained unchanged between the two viruses. Thus, 
all cis-acting elements for controlling viral transcription, replication and encapsidation were 
identical in the two viruses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To establish a reverse genetics system based on the A75/17-V strain, a plasmid coding for the 
full-length antigenome of A75/17-V was constructed. The use of antigenome encoding 
vectors has been demonstrated to be a prerequisite for recovery of infectious negative-strand 
RNA viruses (15, 31, 63, 81, 100, 131, 168, 177, 188, 212, 233). This is mainly due to the fact 
Table 2. Comparison of nucleotide and deduced amino acid sequences between A75/17 and 
A75/17-V CDV
2275 U C P
V
C
H
H
P
V
P
V
M
M
M
L
M
M
M
L
2381
2399
3610
4422
4434
14940
U C
U C
A G
C A
C A
G C
194
194
200
200
  60
331
335
1971
Nucleotide Amino Acid
159
159
Y
Y
L P
L P
V A
V A
E G
L I
L I
E Q
Gene Position A75/17 A75/17-V Protein Position A75/17 A75/17-V(1) (2)
(1) Nucleotide position in the entire genome
(2) Amino Acid position in each protein
(3)
(3) Silent mutation
151 I I
P/V/C
P/V/C
P/V/C
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that the use of genome-encoding vectors results in premature termination of transcription by 
the T7 RNA polymerase at or near intergenic junctions (233). 
In order to clone the full-length genome, an intermediate vector was constructed by 
synthesizing a multiple cloning site (MCS) in the pBluescript II SK+ vector (Stratagene, La 
Jolla, CA), thus allowing a stepwise cloning strategy (Fig. 3A). The T7 promoter, leader, 
trailer, hepatitis delta virus ribozyme sequence and the T7 termination sequence were first 
cloned into this vector. Six cDNA fragments corresponding to the six A75/17-V genes were 
amplified by RT-PCR of RNA obtained from A75/17-V infected Vero cells. Each fragment 
containing the appropriate restriction sites was then cloned into a pGem-T easy vector 
(Promega, Madison, Wisconsin), sequenced and assembled into the MCS, thus engineering a 
vector coding for the full-length antigenome (Fig. 3B). In this construct, the CDV genes are 
separated by unique restriction sites that are located outside the transcription regulatory 
sequences. An additional transcription unit coding for the enhanced green fluorescent protein 
(BD Biosciences, Clontech, Palo Alto, CA) was then inserted at the 3’ proximal position of 
the A75/17-V genome. The resulting plasmid (Fig. 3C), which was designated pgA75/17-V3, 
was sequenced. This showed that, in addition to the 27 nucleotide changes resulting from the 
restriction sites introduced between the genes, 4 silent mutations were present in the F, H and 
L genes at nucleotides 6152 (T-C; F gene), 8053 (A-G; H gene), 14558 (A-G; L gene), 15473 
(T-C; L gene), and 2 in non-coding regions at nucleotides 4148 (T-G) and 7800 (A-C). The 
two latter mutations are located outside the transcription regulatory sequences.  
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Figure 3. Cloning strategy and full-length A75/17-V cDNA. (A) Six cDNA fragments corresponding 
to the six A75/17-V CDV genes flanked by unique restriction sites are shown. The intermediate vector 
containing the newly synthesized multiple cloning site (MCS) is also shown. The T7 promoter (T7) 
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C
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and the A75/17-V leader were cloned as synthetic oligonucleotides. The T7 transcription termination 
signal (Tφ) and the hepatitis delta virus ribozyme sequence (δ) were isolated by PCR amplification 
from plasmid p(+)MV (177) using a primer that also contained the A75/17-V trailer sequence. The 
amplification product was cloned into the intermediate vector. (B) The full-length cDNA clone 
pA75/17-V1 was generated in six separate cloning steps. The restriction sites used for cloning are 
indicated. The FseI and NruI sites were subsequently mutated back to the A75/17-V sequence by site-
directed mutagenesis (Stratagene, La Jolla, CA) to generate pA75/17-V2 and pA75/17-V3, 
respectively. (C) Construction of plasmids pgA75/17-V. An eGFP transcription unit (ATU) was 
inserted into the NruI restriction site between the leader and the N gene of pA75/17-V2. The ATU was 
generated by PCR amplification of the eGFP gene using a 5’ primer containing a NruI site and the 
regulatory G(N)5 sequence motif. The 3’ primer included synthetic gene end (GE) and gene start (GS) 
sequences of the N gene, as well as a NruI site. The PCR fragment was cloned into the NruI site of 
plasmid pA75/17-V2, resulting in plasmid pgA75/17-V2. The NruI restriction sites were subsequently 
mutated back to the A75/17-V sequence by site-directed mutagenesis (Stratagene, La Jolla, CA) to 
generate pgA75/17-V3. The length of the cloned genomes respects the rule of six (124). The first and 
last nucleotides of the RNA expressed from each cDNA clone are indicated. Note that the plasmid 
inserts are not drawn to scale. 
 
To rescue negative-strand RNA viruses, N, P and L proteins have to be provided in addition 
to the plasmid encoding the full-length antigenome (15, 31, 63, 81, 100, 131, 168, 177, 188, 
212, 233). The A75/17-V N, P and L genes were therefore cloned into the pTM-1 expression 
vector (153), yielding plasmids pTM-N, -P and -L. The functionality of the N, P and L 
proteins was confirmed by showing their ability to rescue a bi-cistronic minireplicon 
construct, containing the eGFP and CAT genes flanked by the two A75/17-V promoter 
regions (C. Zweifel, manuscript in preparation).  The P and L genes contained in plasmids 
pTM-P and pTM-L were then mutated to produce the wild-type A75/17-CDV P and L 
proteins, which were shown to yield an enhanced polymerase activity compared to those of 
the Vero cell-adapted virus (C. Zweifel, manuscript in preparation).  
In order to rescue the virus, Bsr-T7/5 cells were selected for initial transfection because of 
their constitutive expression of the T7 RNA polymerase (31). However, initial infection 
experiments with A75/17-V followed by immunofluorescence staining revealed a very limited 
non-cytolytic infection in these cells. Thus, as expected, after transfection of Bsr-T7/5 cells 
with plasmids pTM-N, pTM-P, pTM-L and pgA75/17-V3 in six-well plates, only single 
eGFP-expressing cells were detected. This suggested that, although rescue had probably 
occurred, the virus was unable to propagate efficiently in these cells. To overcome this 
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problem, two days after transfection, 106 Bsr-T7/5 cells were transferred to a 10 cm dish in 
which Vero cells had been seeded at 50-60% confluency. In addition, 4 hours post-
transfection and before co-culture, the Bsr-T7/5 cells were heat shocked at 43°C for 2 hours, 
which has been shown to enhance the efficiency of recombinant virus rescue (161, 162). As 
no syncytia were observed upon co-culture of Bsr-T7/5 and Vero cells, the presence of 
rescued viruses was monitored using an inverted fluorescence microscope. Five days post-
transfection, four independent foci were identified, each consisting of about 20 eGFP-
expressing cells. The successful rescue of recombinant eGFP-expressing A75/17-V virus 
from the co-cultured Bsr-T7/5 and Vero cells indicated that transfected Bsr-T7/5 cells had 
yielded at least one infectious unit or generated at least one functional nucleocapsid template, 
which could then be transferred to a neighboring Vero cell by some unknown mechanism. 
Once in Vero cells, the virus was apparently able to replicate and spread to further cells. The 
virus from one of the foci was selected for further studies, designated rgA75/17-V, and 
amplified by three additional passages in Vero cells.  
The recombinant eGFP-expressing virus was next characterized. First, viral RNA was 
extracted from parental A75/17-V and rgA75/17-V infected Vero cells. RT-PCR was 
performed in a region containing the MluI restriction site (Fig. 4), which had been introduced 
into the recombinant genome. DNA fragments were then digested with MluI. The enzyme 
cleaved only fragments amplified from recombinant viruses (Fig. 4A). No fragment was 
amplified in control experiments in which the reverse transcriptase was omitted, excluding 
plasmid contamination. The identity of the recombinant virus was then confirmed by reverse 
transcription-PCR and sequence analysis of the P, M, F and H genes, which showed that no 
point mutations had occurred compared to the transfected plasmid. As an example, the 
presence of the engineered PmeI restriction site is showed in Fig. 4B. Taken together, these 
results demonstrate that the recombinant virus is derived from the cloned full-length cDNA 
and confirmed the authenticity of our plasmid-based recovery system. 
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Figure 4. Characterization of rgA75/17-V. (A) Analysis of a RT-PCR fragment containing the MluI 
restriction site in recombinant virus. The corresponding region of the parental virus was also 
amplified. The PCR products were incubated with MluI (lane 3 and 6) or buffer alone (lane 2, 5). To 
demonstrate the absence of full-length plasmid contamination, PCR reactions were also performed 
without reverse transcriptase (-RT, lane 4, 7). The sizes of the uncleaved PCR fragment and MluI 
digestion products are shown at the right. M, 1 kb ladder marker. (B) Electropherogram showing the 
nucleotide sequence of the intergenic region between the P and M gene of recombinant virus. The 
PmeI restriction site in recombinant virus is indicated.  
 
To further characterize the recombinant virus, the structural proteins N, M, F and H proteins 
of recombinant and parental virus were analyzed by western blotting. The analysis revealed 
an identical apparent molecular size between the proteins of parental and recombinant virus 
(data not shown).  
Titration of cell-associated viruses, which were recovered from cells lysed by three cycles of 
freezing and thawing, showed that rgA75/17-V replicated efficiently and displayed growth 
kinetics similar to those of the parental A75/17-V isolate (Fig 5). However, in three 
independent experiments, the titers of the parental virus were consistently slightly higher than 
the titers obtained for the recombinant virus in the initial phase of infection. Nevertheless, at 4 
and 5 days post infection, both virus titers reached a similar plateau.   
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Figure 5. Time course of cell-associated virus production in Vero cells infected with parental and 
recombinant virus. Vero cell were infected at an MOI of 0.01, and virus titers were determined at the 
indicated times post-infection by immunocytochemistry for both A75/17-V and rgA75/17-V. The 
titers represent the average of three independent experiments. 
 
Finally, to compare the phenotype of the parental and recombinant viruses, infected Vero 
cells were analyzed by phase contrast microscopy (Fig. 6A, 1-3), immunocytochemistry using 
a monoclonal antibody directed against the CDV N protein (Fig. 6A, 4-6), and by 
fluorescence microscopy in the case of rgA75/17-V (Fig. 6B). The results obtained by all 
three methods demonstrated that there was no obvious syncytium formation in the rgA75/17-
V infected cells, suggesting that A75/17-V recovered from cDNA reproduced the same 
phenotype as the parental virus in Vero cells.  
 
 
 
 
 
 
 
 
 
 
 
 
A75/17-V
rgA75/17-V
1
2
3
4
5
V
iru
s 
ti
te
r (
lo
g 
10
 in
fe
ct
io
us
 u
ni
ts
/m
l)
Time (days post infection)
6
1 2 3 4 50
7
A
A75/17-V rgA75/17-V ni
3 dpi
1 2 3
4 5 6
 48
 
 
 
 
 
 
 
 
 
Figure 6. Characterization of A75/17-V and rgA75/17-V persistent phenotype. (A, panels 1-3) 
Representative phase contrast microscopy views of Vero cells infected with parental A75/17-V, 
rgA75/17-V or non-infected cells (ni) at 3 days post infection (dpi) are shown. (A, panels 4-6) 
Immunocytochemistry of Vero cells infected with parental A75/17-V, rgA75/17-V or non-infected 
cells using anti-CDV N protein monoclonal antibody at 3 dpi are shown. (B) Vero cells infected with 
rgA75/17-V is observed under phase contrast microscopy (panel 1) and fluorescence microscopy 
(panel 2) at 4 dpi. The images were combined by using the Leica FW4000 software (panel 2). For each 
experiments, cells were infected at an MOI of 0.01. 
 
In this study, we report the sequence comparison of the virulent A75/17 CDV strain and its 
Vero cell-adapted derivative A75/17-V, as well as the rescue of the latter virus from cloned 
cDNA. Since the infection of Vero cells with A75/17-V virus is characterized by the absence 
of syncytia formation, an additional transcription unit coding for the enhanced green 
fluorescent protein was inserted into the CDV genome to facilitate the tracking of 
recombinant virus. This eGFP-based strategy has already been used for the rescue of many 
other negative-stranded RNA viruses and allowed both the isolation of a molecular clone of a 
persistent virus and the study of cell-to-cell spread in real time.  
Comparison of the biological properties of the recombinant and the parental virus showed that 
the recombinant virus exhibited the same cell tropism not only in Vero cells, but also in CHO, 
DH82 and MDCK cells (data not shown) and, most importantly, exhibited the same persistent 
phenotype in all cell lines. Whereas infection with OP-CDV results in very rapid formation of 
large syncytia followed by cell lysis, the infection with A75/17-V and rgA75/17-V virus 
induced clusters of single infected cells with no obvious formation of syncytia. However, the 
possibility that passage of infected cells may eventually also produce a cytopathic effect 
cannot be excluded. In this study, we have focused on the initial phase of infection to avoid 
B
rgA75/17-V
1 2
4 dpi
 49
selecting for virus mutants, which may exhibit biological properties that are not characteristic 
of the parental virus. Indeed, we have shown that serial passages of the virus do generate such 
mutants (see below).  
Growth kinetics in Vero cells showed similar properties, with a slightly slower replication rate 
for the recombinant virus (Fig. 5). This delay in virus production of the cloned virus might be 
explained by the fact that the additional transcription unit is located at the 3' proximal position 
of the genome, thus possibly influencing transcription. On the other hand, we cannot rule out 
the possibility that the two mutations in the non-coding region and the engineered restriction 
sites, although located outside regulatory elements, may play a role in the slightly delayed 
growth kinetics by influencing transcription, as has been proposed for VSV (Harmon et al., 
2002). 
A75/17-V was obtained after 17 passages and differs in only 7 amino acids from the highly 
virulent A75/17-CDV. In addition, the virus has been reported to be attenuated in vivo and no 
longer neurotropic (98). Therefore, amino acid changes in the P, V, M and L proteins between 
the wild-type and the Vero cell-adapted virus seem to play a crucial role in CDV 
pathogenesis. It has recently been shown that the attachment (H) protein of OP-CDV is the 
major determinant of cell tropism and cytopathogenicity (230). Surprisingly, sequence 
comparison between the A75/17 and A75/17-V strains revealed no difference in the H and F 
surface glycoproteins, thus indicating an as yet unknown H protein-independent mechanism 
of virus adaptation in cell culture, which also results in reduced pathogenicity in vivo. 
Interestingly, the wild-type IC-B strain of measles virus and its Vero cell-adapted derivative 
IC-V were shown to contain only 2 mutations located in the coding sequences of the M and 
P/V/C genes (215). Importantly, the IC-V strain did not cause any clinical signs in infected 
monkeys (123). These observations are inconsistent with the notion that the host cell 
specificity of MV and CDV is determined exclusively by the H protein, and underline the 
crucial importance of being able to manipulate a molecular clone derived from a highly 
virulent CDV isolate to study mechanisms of pathogenicity.  
Recombinant viruses expressing eGFP have already been demonstrated to be useful for the 
study of measles virus dissemination in vitro and in vivo (59-62, 64, 171, 187). We therefore 
believe that our engineered virus will be a particularly valuable tool to investigate 
determinants of persistent infection. In this context, two lines of research have been 
developed. Firstly, by repeated passages of rgA75/17-V in Vero cells, we obtained a variant 
virus inducing cell-to-cell fusion. Sequence comparison of the P, M, F and H genes of this 
mutant with the parental virus revealed two nucleotide differences resulting in amino acid 
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changes in the F and H proteins. Transient expression of parental and mutant F and H proteins 
clearly demonstrated that both amino acid changes were needed for syncytia formation. 
Secondly, we took advantage of the highly cytolytic phenotype of the OP-CDV vaccine strain 
to determine the role of the surface glycoproteins in producing a cytolytic versus persistent 
infection. Towards this end, recombinant viruses based on the genetic background of the 
A75/17-V virus with heterotypic combinations of F and H proteins were generated from 
cDNA, and the phenotypes of these viruses were analyzed in different cell lines (manuscript 
in preparation). Moreover, chimeric viruses bearing the matrix (M) and/or the polymerase (P 
and L) genes of the wild-type virus are currently being generated and will allow us to dissect 
the molecular mechanism involved in CDV virulence in dogs. 
 
We thank H. Naim for essential help in establishing the CDV rescue system, M. Billeter, K. 
Conzelmann and B. Moss for providing valuable reagents, H. Naim and J-P. Rivals for critical 
reading of the manuscript and J. Masternak for technical assistance.  
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3.1.2 Personal contribution to this article and perspectives 
In this article as a second author, my contribution was based mainly on the construction of the 
different plasmids. At the beginning, Philippe Plattet and I had the same thesis project 
consisiting in the establishment of a rescue system for the Vero cell-adapted A75/17-V CDV. 
For that purpose, all the constructs had to be cloned in our laboratory. First, the expression 
plasmids encoding the N, P and L proteins were constructed; I was particularly focused on the 
P and L genes, which had to be obtained by RT-PCR from the virus stock. The functionality 
of these plasmids was tested in a minigenome assay, which has been completely set up by our 
hands. Then, RT-PCR was proceeded on the six different genes, which were cloned in a 
pBluescript plasmid by the introduction of specific restriction sites. The genes have been 
sequenced and introduced mutations have been corrected. Once the full length plasmid has 
been obtained in close collaboration with Philippe Plattet, the conditions for resucing the 
recombinant virus has been mainly established by Philippe Plattet. My last contribution was at 
the level of recombinant virus characterization by some sequencing and 
immunocytochemistry. Finally, I helped at the redaction level by a critical reading and 
creation of tables and figures. 
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The establishment of a rescue system was essential in order to study canine distemper virus 
pathogenesis. A rescue system already exists for the vaccine strain of CDV, but this strain 
presents only 93% homology with the wild-type canine distemper virus. Thus, the Vero cell-
adapted A75/17-V strain represents a better model to study virus pathogenesis. This system 
will help us understanding the adaptation process by mutating the P, M and L genes in order 
to also obtain the rescue system of the wild-type virus strain itself.   
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3.2 DECREASE IN POLYMERASE ACTIVITY UPON CELL CULTURE ADAPTATION OF 
WILD-TYPE CANINE DISTEMPER VIRUS 
3.2.1 Comparison of A75/17 CDV and A75/17-V CDV 
The adaptation of the wild-type A75/17 CDV in Vero cells gave rise to a new virus strain, the 
A75/17-V CDV (98), which exhibits major differences in the symptoms in dogs as well as in 
growth in cell lines (table 3). Moreover, all these differences were only due to seven amino 
acid changes (170). The wild-type virus was not able to grow in cultured cell lines such as 
Vero and CHO cells, in contrast to primary cells such as dog brain cell culture (DBCC) and 
dog keratinocytes, as well as CHO cells stably expressing the dog SLAM receptor. The most 
interesting difference between these two virus strains was the uncapacity of the adapted virus 
to enter the central nervous system of the dog. However, this has only been tested in two 
experimental dogs and it probably needs to be confirmed (98).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics A75/17 A75/17-V
* Growth in Vero cells
CHO-SLAM cells
Symptoms and histopathology 
in dogs 
immunosuppression
Virulence
fever and respiratory signs
body weight loss
neurological symptoms
+
+-
+
+
+
+
+
-
-
+ -
-
Table 3. Comparison of wild-type A75/17 CDV and Vero cell-adapted A75/17-V 
CDV with respect to growth in cell lines and pathogenicity for dogs
+
Primary Dog keratinocytes ++
Primary Dog Brain cell culture ++
CHO cells +/--
* at a MOI of 0.0001(titrated in CHO SLAM cells)
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These two virus strains were studied in Vero cells where the adaptation has taken place. After 
11 days of infection, no foci could be detected for A75/17 CDV (figure 7, panel 8) and this 
absence of infection was still observed 3 weeks post infection (data not shown). In contrast, 
A75/17-V CDV infected very efficiently Vero cells as shown in figure 7 where some foci 
could already be detected 4 days post infection (panel 3) and at 7 days of infection, almost 
50% of the cells were infected (panel 6). At day 7, the cell confluency was so high that the 
cells needed to be trypsinized and split to a third in a new 6-well culture dish. After 
trypsinization, the cells had some difficulties to adhere to the new well, grew more slowly and 
got all infected at 11 days post infection (figure 7, panel 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Infection of Vero cells with A75/17 CDV and A75/17-V CDV. Vero cells were infected 
with both virus strains at a m.o.i of 0.0001 as titrated in CHODogSLAM cells. After 4, 7 and 11 days 
of infection, viruses were detected by immunocytochemistry with an anti-N D110 mAb.. 
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Upon cell culture adaptation, the amino acid differences between the A75/17 CDV and the 
A75/17-V CDV strains were located in the P, V, M and L proteins. As the mutations in the P 
and L proteins affected the CDV RNA dependant RNA polymerase (RdRp), my project was 
based on the study of polymerase activity of CDV and on the role of these mutations 
following cell-culture adaptation.  
The mutations in the P protein were located at amino acids 159, 194, and 200, and at amino 
acid 1971 for the L protein. By comparison of the P and L amino acid sequences in the 
Morbillivirus genus, only two amino acid differences affected conserved residues (table 4). In 
the P protein, the amino acid 194, which was a leucine for every Morbilliviruses presented a 
proline in A75/17-V CDV and the glutamate at amino acid 1971 of the L protein was a in 
A75/17-V CDV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, the Ondersteeport CDV strain, which is a vaccine strain with 93% of homology 
with the A75/17 CDV strain, had the same amino acid residues at these four positions as the 
wild-type A75/17 CDV strain, although the vaccine strain was passaged many times and was 
able to grow very efficiently in Vero cells (data not shown). 
 
A 75/17 CDV  
A 75/17-V  CDV
Measles virus (all strains)
R inderpest virus
Phocine distemper virus
Dolphin distemper virus
Peste des petits ruminants virus
159
P/V
194 200
T yr
His
A sp
A sp
T yr
A sp
A sp
V al
A la
L ys
L ys
A la
I le
Gly
L eu
Pr o
L eu
I le
L eu
L eu
L eu
L
1971
Glu
G ln
Glu
Glu
A mino acid position
T able 4. A mino acid sequence comparison in the Morbillivirus genus
Glu
Glu
Glu
* amino acids mutated in CDV  that affect conserved residues in the 
Morbillivirus genus
**
Onderstepoort CDV                                                 T yr V al L eu Glu
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3.2.2 Establishment of a minireplicon assay to test polymerase activity 
In order to better understand the cell culture adaptation process of the wild type A75/17 CDV 
strain, polymerase activity of both CDV strains was investigated with the use of a 
minireplicon assay. This system is based on the cotransfection of a minireplicon plasmid 
together with expression plasmids encoding the N, P and L proteins of either the A75/17 CDV 
or the A75/17-V CDV strains. The minireplicon as well as the N, P and L genes cloned in 
expression plasmids were under a T7 promoter and in order to respect the rule of six of the 
minigenome (33, 124, 231), the hepatitis delta ribozyme (an autocatalytic RNA) was placed 
before the T7 teminator sequence. Vero cells were primarily infected with a modified vaccinia 
virus, called the Ankara strain (MVA) recombinant for the T7 RNA polymerase, which 
allowed transcription of the minireplicon as well as of the N, P and L genes. The expression 
of the N, P and L proteins was tested by Western blotting and were efficiently prodeuced in 
Vero cells (data not shown).  
The minireplicon plasmid used in this assay was first a monocistronic negative minireplicon 
plasmid (pCAT(-)) containing the chloramphenicol acetyl transferase gene (CAT) as a 
reporter gene (Figure 8A). This gene was flanked by the two promoter regions of CDV, the 
genome and the antigenome promoters, and was under the T7 promoter in 3’. Unfortunately 
the background values observed with negative controls were very high, approaching the value 
of the positive control, the A75/17-V CDV polymerase as shown in figure 8B. Indeed, this 
was consistent with an OP-CDV based minireplicon construct tested in our laboratory as well 
as by Gassen et al (82). In fact, it has been proved that the MVA polymerase could recognize 
an homogenic sequence in the genome promoter of CDV (data not shown). The MVA-
dependent minireplicon transcript could then be translated by the cellular machinery thus 
producing a lot of non-specific CAT proteins.  
 
 
 
 
 
 
 
 
 
CAT gene
Leader Trailer
Start N Stop L
 genome
promoter
antigenome 
  promoter
T7 promoter
Ribozyme
T7 terminator
minireplicon negative
pCAT (-)
(4000 bp)
amp R
A
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Figure 8. Setup of the minireplicon assay. (A) The minireplicon negative pCAT(-) contained a CAT 
reporter gene flanked by the promoter regions of CDV and is under a T7 promoter in 3’ (B) Vero cells 
were first infected with MVA (m.o.i of 1.5) and transfected with different plasmids using the 
lipofectamine 2000 reagent : 300 ng CAT(-), 100 ng of pTM-N, 100 ng of pTM-P of A75/17-V CDV, 
25 ng of pTM-L of A75/17-V CDV. The cells were incubated 24 hours at 37 °C, lysed and the 
proteins analyzed. The β-galactosidase was measured with CPRG at 595 nm and the CAT was 
quantified by a CAT ELISA (Roche) at 405 nm. The OD405 was normalized with OD595 and the results 
were presented as concentrations of CAT deduced from a standard curve. 
 
The new strategy was to construct a bicistronic positive minireplicon plasmid containing the 
CAT gene in the second position in order to minimize the transcriptional effect of MVA. In 
this case, MVA-T7-dependent transcription would probably result in eGFP-CAT readthrough 
transcripts, from which the secondly placed CAT gene would be drastically less translated. 
Finally, CAT production will mainly depend on CDV RdRp transcription. 
The bicistronic positive minireplicon plasmid called peGFP/CAT(+) contained from 5’ to 3’ a 
T7 promoter, the genome promoter of CDV, the eGFP gene, the intergenic region of the N 
gene, the CAT gene, the antigenome promoter, a ribozyme and a T7 terminator (figure 9A). 
In figure 9B, the negative controls were done using the peGFP/CAT(+), MVA as the provider 
of the T7 RNA polymerase and one of the three expression plasmids encoding the N, P and L 
proteins of either the A75/17 CDV or the A75/17-V CDV strains. The positive control 
consisted in the polymerase activity of A75/17 CDV and not of A75/17-V CDV as presented 
for the pCAT(-). However, compared to the minireplicon negative (figure 8B), this clearly 
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showed that the use of a bicistronic positive minireplicon could completely eliminate the 
background level due to MVA. This system was thus used for the following experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Setup of the minireplicon assay. (A) The minireplicon positive plasmid peGFP/CAT (+) 
contained a minireplicon positive from 5’ to 3’ : the genome promoter of A75/17 and A75/17-V CDV, 
an eGFP gene, an intergenic region of the N gene, a CAT reporter gene, the antigenome promoter 
flanked by a T7 promoter and a ribozyme downstream a T7 terminator. This plasmid was used in 
every conditions of transfection. (B) Vero cells were first infected with MVA (m.o.i of 1.5) and 
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transfected with different plasmids using the lipofectamine 2000 reagent : 300 ng peGFP/CAT(+), 100 
ng of pTM-N, 100 ng of pTM-P of A75/17 or A75/17-V CDV, 25 ng of pTM-L of A75/17 or A75/17-
V CDV. The cells were incubated 24 hours at 37 °C, lysed and the proteins analyzed. The β-
galactosidase was measured with CPRG at 595 nm and the CAT was quantified by a CAT ELISA 
(Roche) at 405 nm. The OD405 was normalized with OD595 and the results were presented as 
concentrations of CAT deduced from a standard curve. 
 
3.2.3 Decrease in polymerase activity upon cell culture adaptation  
The minireplicon assay established in Vero cells allowed the comparison of polymerase 
activities from the A75/17 and the A75/17-V CDV strains simply by cotransfecting either the 
N, P and L expression plasmids of either the A75/17 or the A75/17-V CDV strains with the 
bicistronic positive minireplicon plasmid. The CAT concentration was normalized to the 
transfection rate by dividing the OD405 by the OD595 of the β-gal measurement. 
As depicted in figure 10, the two first columns represent the negative controls of each 
polymerases without the expression plasmid encoding the L protein. This gave the CAT basal 
level representative of a non-functional polymerase. Then, polymerase activities of the 
A75/17 and the A75/17-V CDV strains were shown in columns 3 and 4 respectively. A 
significantly much higher CAT concentration was obtained for the A75/17 CDV strain than 
for the A75/17-V CDV strain, representing a 10-fold decrease in polymerase activity due to 
the four mutations located in the P and L proteins. 
In order to rule out the possibility that the observed differences in polymerase activity were 
due to different expression levels of the N, P and L proteins, Western blottings were 
performed for each transfection experiments (figure 10). Cellular tubuline served as an 
internal control; this analysis showed that all proteins were expressed in similar amounts in 
transfected cells. The anti-N protein antibody revealed a band at 62kDa, the anti-L protein 
antibody at 220kDa and the anti-P protein antibody revealed two bands at 80 and 62kDa, 
representing the phosphorylated and the non phosphorylated forms of the protein, 
respectively.  
We concluded from the Western blottings that the differences in RNA polymerase activity 
between the wild-type and the adapted virus strains were not due to different levels of protein 
expression but that they were true properties of the corresponding viral enzymes. Thus, 
unexpectedly cell culture adaptation of the wild-type strain led to a decrease in RNA 
polymerase activity. 
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Figure 10. Polymerase activity of A75/17 and A75/17-V CDV. Vero cells were first infected with 
MVA, then CMV βgal, peGFP/CAT(+) and pTM-N were cotransfected in column 1 with pTM-P of 
the A75/17 CDV strain, in column 2 with pTM-P of A75/17-V, in column 3 with pTM-P and pTM-L 
of the A75/17 CDV strain and in column 4 with pTM-P and pTM-L of the A75/17-V CDV strain. 
After 24 hours of transfection, cells were lysed. The β-galactosidase was measured at 595 nm and the 
CAT at 405 nm. The absorbances at 405 nm were normalized with the absorbances at 595nm and the 
values were converted in CAT concentration in reference to the standard curve. 
Western blots were done on the four different cell lysates after quantification of the total proteins by 
Bradford and migration on SDS PAGE (10 % acrylamide and 6 % for the L protein). 
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Immunodetection was made with an anti-N D110 monoclonal antibody (1 :100), an anti-P mouse 
monoclonal 4.415 (1 :200), an anti-L poylclonal antibody (1 :1000) and an anti-β tubuline monoclonal 
antibody (1 :3000). 
* p < 0.005 
 
3.2.4 Decrease in transcription and replication activities upon cell culture adaptation  
The minireplicon assay demonstrating that the RdRp of the Vero cell-adapted virus had a 
lower activity did not allow distinguishing between transcription and replication activities. 
In order to investigate transcription activity of the RdRp within the minireplicon assay, an 
RNase protection assay (RPA) was performed. The probe was designed in the peGFP/CAT 
(+) and hybridized to different transcripts as described in figure 11A. Since the probe was 
hybridized to total RNA, replicated minigenome of positive polarity will also be detected. 
However, as the probe also contains a part of the eGFP gene, the replicated protected 
fragments will be longer in size as compared to the protected CAT transcripts. Finally a probe 
for the cellular ribosomal L27 RNA was used as an internal control. 
Figure 11B shows the results of the RNase protection assay. The undigested probes migrated 
at 383nt for the eGFP-CAT probe (lane 1) and at 350nt for the L27 probe (lane 2). Different 
negative controls were added in order to identify the CDV specific bands. First, a control 
without MVA has been done which only showed a band at 290nt representing the protected 
L27 RNA (lane 3). In the presence of MVA, two RNase resistant fragments of 323nt and 
275nt were detected (lane 4). As these fragments were present even in the absence of the 
CDV polymerase, they were definitely assumed as MVA-T7 dependent RNAs. The CDV 
CAT transcript migrated at 265nt and could be easily distinguished from the other 
background bands. Significantly, this band was absent for the negative control without the L 
expression plasmid (lane 5), very faint for the A75/17-V CDV polymerase (lane 7) and 
strongly present for the A75/17 CDV polymerase (lane 8). This technique showed that the 
RdRp of the wild-type virus had a higher transcription activity than that of the cell-culture 
adapted virus, consistent with the higher overall activity determined in the minireplicon assay. 
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Figure 11. Transcription and replication activity of CDV polymerases. (A) Transcription was 
quantified by an RNase protection assay. Digested products are presented. (B) Lanes 1 and 2 
corresponded to the undigested eGFP-CAT probe (383nt) and L27 probe (350nt) respectively. Lanes 3 
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and 4 represented the peGFP-CAT (+) transfected without or with the prior MVA infection. The 
negative control of the minireplicon assay without the pTM-L expression plasmid was shown in lane 5 
and the positive controls (the A75/17 and A75/17-V CDV polymerases) in lanes 6 and 7. (C) 
Replication was studied using the micrococcal nuclease digestion . The minireplicon assay was 
proceeded in Vero cells with the two positive controls and one negative control for 24 hours. CAT 
RNA was amplified in the MCN S7 treated sample and L 27 RNA in the untreated sample. RT-PCR 
products migrated on a 1 % agarose gel. 
 
Replication of the A75/17 and the A75/17-V CDV polymerases was also investigated using 
the fact that replicated RNA molecules are encapsidated by multiple N proteins and thus 
resistant to digestion by the microccal nuclease (11). Toward this end, the minireplicon assay 
was performed in Vero cells and the cell lysates were digested or not by the microccal 
nuclease. The presence of CAT replicated strands were tested by RT-PCR on the treated 
samples. Negative controls without the RT step were added for each treated samples to ensure 
the absence of any DNA contamination, and indeed no amplification products were detected 
(data not shown). As shown in figure 11C, the L27 RNA, serving as an internal standard, was 
amplified by RT-PCR in the untreated samples and was of the same intensity for the three 
conditions tested. For the CAT replicated RNA, no band was detected in the sample without 
the L encoding plasmid. Significantly, the band obtained with RNA isolated from cells 
expressing the A75/17 polymerase was stronger than that from cells expressing the A75/17-V 
polymerase.  
Taken together, these results thus confirmed that the polymerase of the wild-type A75/17 
CDV strain had a higher activity, which results from both a higher transcription and 
replication activities.  
 
3.2.5 Decrease in polymerase activity due to the mutations in the P protein 
As determined with the minireplicon assay, cell culture adaptation led to a decreased 
polymerase activity in Vero cells due to four mutations located in the P and L proteins. In 
order to investigate which protein was responsible for this decrease in polymerase activity, 
different combinations of the P and L expression plasmids of A75/17 and A75/17-V CDV  
were cotransfected in Vero cells and represented activities of chimeric polymerases. 
As shown in figure 12A, the chimeric polymerase composed of the P protein of A75/17 CDV 
and the L protein of A75/17-V CDV had a similar high activity as the wild-type polymerase 
 63
(column 6 compared to column 3). In contrast, the chimeric polymerase composed of the P 
protein of the A75/17-V CDV strain and the L protein of the A75/17 CDV strain exhibited a 
very low activity whose activity could be compared to the cell-culture adapted polymerase 
(column 5 compared to column 4); this polymerase is so called the low active chimeric 
polymerase. The Western blotting analysis confirmed that the observed differences in 
polymerase activity were not due to differences in protein expression levels (figure 12A). 
These results thus showed that the P protein determines the polymerase activity and that the 
mutations in the L protein is not important for the decrease in polymerase activity upon cell-
culture adaptation. 
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Figure 12. Activity of chimeric polymerases. (A) Polymerase activity has been assessed by the use of 
a minireplicon assay. Western blots were performed for each conditions. * p < 0.05. (B) Transcription 
was measured by RNase protection assay with an eGFP-CAT probe and a L27 internal probe. (C) 
Transfected cells were treated with MCN and CAT replicated strands were amplified by RT-PCR. 
 
Transcription and replication activities have been assessed for both chimeric polymerases 
(figure 12B et 12C). Again, transcription was studied by RNase protection assay and the 
chimeric polymerases were presented in lanes 8 and 9 (figure 12B). Determination of 
replication was done by treatment of cell lysates with Mnase and the high and the low active 
chimeric polymerases were shown in lanes 4 and 5, respectively (figure 12C). The active 
polymerase showed a marked transcription and replication in contrast to the low active 
polymerase, which had only a weak transcription and replication. 
In conclusion, it has been proved that the P protein is a major determinant of polymerase 
activity, and modulates both transcription and replication activity. The P protein of the wild-
type virus thus conferred a high activity to the polymerase complex in contrast to the P 
protein of the Vero cell-adapted virus, which lowered drastically the polymerase efficiency. 
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3.2.6 Interaction of the N and P proteins in Vero cells 
The RdRp of canine distemper virus is composed of the P and L proteins, which are bound to 
the nucleocapsid by the interaction of the P protein with the N protein. In the study of 
polymerase acitivity, it was interesting to look at the interactions between the proteins 
forming the polymerase complex, however, only the N and P proteins of A75/17-V are 
presented below. An immunoprecipitation method has been successfully set up to demonstrate 
N/P complexes. 
After transfection of expression plasmids encoding either the N or the P proteins and 
radioactive labelling with 35S-methionine and cysteine, Vero cells were lysed and 
immunoprecipitated with an anti-N antibody followed by an incubation with sepharose beads 
coupled to protein G in order to isolate the N-P complexes. The proteins were then revealed 
after migration on a SDS-PAGE gel and autordiography. 
Immunoprecipitated proteins were represented in figure 13A under reducing and non-
reducing conditions. A negative control was done for both conditions corresponding to the 
transfection of an empty expression vector, for which no band could be detected after 
immunoprecipitation. The expression of the N protein alone revealed two bands at 62 kDa 
and 60 kDa in both conditions, representing two forms of the N protein. When coexpressed 
with the P protein, only one band could be detected for the N protein migrating at 62 kDa. 
The P protein, which was coprecipitated with the N protein migrated at 80 kDa under 
reducing conditions and at >200 kDa under non reducing conditions, revealing the presence of 
complexed P proteins. 
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Figure 13. Co-immunoprecipitation of N and P proteins. (A) Vero cells were transfected with an 
empty expression plasmid (pTM-1), with an expression plasmid encoding the N protein (pTM-N) and 
with expression plasmids encoding the N and the P proteins (pTM-N and pTM-P) for 24 hours and 
radioactively labelled for 4 hours. The cell lysates were immunoprecipitated with an anti-N antibody 
and proteins were revealed by SDS-PAGE under reducing and non reducing conditions. (B) 
Expression plasmids encoding truncated P proteins in the N terminal part or in the C terminal part 
were cotransfected with pTM-N and revealed under reducing conditions after immunoprecipitation. 
 
In order to characterize the N-P interaction, two mutants of the P proteins were constructed: a 
P protein deleted of its amino-terminal part from aa 1 to 60 (pTM-P Nter) and a P protein 
deleted of its carboxyl-terminal part from aa 432 to 508 (pTM-P Cter). The expression 
plasmids encoding these two mutants of a molecular weight of about 75 kDa and the N 
protein were cotransfected and coimmunoprecipitated with the anti-N antibody. A similar 
expression of these two mutants was shown in Vero cells before any further experiment (data 
not shown). As controls, the three previous conditions were used and exhibited the same 
pattern as presented in figure 13B. The N terminal mutant only revealed one band 
corresponding to the N protein, but no P protein was present. In contrast, the C terminal 
mutant could still bind to the N protein and migrated at 75 kDa under reducing conditions. 
These results highlighted an important domain in the N terminal part of the P protein, 
indispensable for binding to the N protein. 
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3.2.7 The mutations in the M protein had no effect on polymerase activity 
During cell culture adaptation of the wild-type CDV virus in Vero cells, three mutations 
occurred in the M protein; the first mutation was located at amino acid 60 and the other two at 
amino acids 331 and 335. By comparison within the Morbillivirus genus, only the first one 
affected a conserved residue (table 5). The glutamate present for all Morbilliviruses was 
changed into a glycine in the cell-culture adapted virus. Interestingly, at this position, the 
vaccine Onderstepoort strain exhibited a phenylalanine, and is thus different to the other 
canine distemper virus strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The M protein, binding the nucleocapsid to the viral glycoproteins in the viral particle, could 
thus not only be involved in virus budding, but also in viral multiplication.  
To better understand cell culture adaptation of canine distemper virus, it was thus necessary to 
check the role of the M protein on polymerase activity by the use of the minireplicon assay. 
An expression plasmid encoding the M protein of either A75/17 or A75/17-V CDV was 
constructed and cotransfected with the expression plasmids encoding each polymerases. As 
shown in figure 14, two concentrations of M expression plasmids were cotransfected, 50ng 
and 100ng. For A75/17-V CDV, 50ng of M expression plasmid slightly increased polymerase 
activity and 100ng slightly decreased polymerase activity, but these differences were not 
A75/17 CDV 
A75/17-V CDV
Measles virus (all strains)
Rinderpest virus
Phocine distemper virus
Dolphin distemper virus
Peste des petits ruminants
Onderstepoort CDV
Amino acid position
M
335331180
Leu
Ile
Leu
Leu
Leu
Leu
Leu
Leu
Ile
Leu
Leu
Leu
Leu
Leu
Glu
Gly
Glu
Glu
Glu
Glu
Glu
LeuLeuPhe
Table 5. Amino acid sequence comparison in the Morbillivirus genus
 68
significant compared to the adapted polymerase (figure 14A). Figure 14B showed that the M 
protein of A75/17 CDV had no effect on its own polymerase at 50ng as well as at 100ng. 
These results were confirmed by Western blottings where comparable levels of protein 
expression were detected for the N, P, M and L proteins. 
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Figure 14. Effect of the M protein on polymerase activity. Minireplicon assays and Western blots 
were done in Vero cells. The expression plasmids encoding the M proteins (pTM-M) of A75/17-V (A) 
and A75/17 (B) were cotransfected with the genes encoding the polymerase of A75/17-V (A) and of 
A75/17 (B), respectively. 50 and 100 ng of pTM-M were used in this assay. 
 
The effect of the M proteins was tested and these M proteins were shown not to be of major 
importance, as they did not significantly modulate polymerase activities. The role of the M 
protein in the cell culture adaptation process has to be found in other viral functions.  
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3.2.8 CHODogSLAM cells allowed comparative infection studies of A75/17 and A75/17-V 
CDV 
Surprisingly polymerase activity of A75/17 CDV was found to be much higher than the 
polymerase activity of A75/17-V CDV in a minireplicon assay. However, this assay is a 
synthetic assay where not all the viral proteins are present. In order to confirm this result in 
the presence of all viral proteins, it could be necessary to work at an infection level. Toward 
this end, a cell line where both viruses could enter at the same rate, the CHODogSLAM cells, 
was used for further experiments with the wild-type and the adapted virus strains; these cells 
are CHODG44 cells stably expressing the canine SLAM receptor.  
It was demonstrated that A75/17 and A75/17-V CDV were not able to infect CHODG44 cells 
at an m.o.i of 0.0001 and that transfection of the canine SLAM receptor allowed both viruses 
to enter CHODG44 cells. A stable CHODG44 cell line expressing the canine SLAM receptor 
was established for comparative studies of the wild-type and the adapted virus strains. 
In order to determine the entry rate of A75/17 CDV and A75/17-V CDV in CHODogSLAM 
cells, these cells were infected in triplicate at a m.o.i. of 0.0001 for different time points (1, 2, 
5, 10, 30 and 60 minutes) and incubated for 24 hours at 37°C. The foci of infection were 
detected by immunocytochemistry, counted and represented in figure 15A. First of all, the 
pattern of virus entry between both virus strains in CHODogSLAM cells was very similar, 
showing the use of the SLAM receptor with comparable efficiency for both virus strains. 
Then, it was observed that one minute of infection was already sufficient for some viruses to 
enter CHODogSLAM cells and that the number of infected cells increased more importantly 
from 30 to 60 minutes. 
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Figure 15. Entry and polymerase activity of A75/17 and A75/17-V CDV in CHODogSLAM cells. (A) 
CHODogSLAM cells were infected with A75/17 and A75/17-V CDV at a m.o.i of 0.0001 for different 
time points (0, 1, 2, 5, 10, 30 and 60 minutes. The virus preparation is then replaced by fresh medium 
for 24h at 37°C. The infected cells were revealed by immunocytochemistry and counted. (B) 
Polymerase activity was determined by minireplicon assay for the polymerase of A75/17 and A75/17-
V CDV. * p < 0.05. 
 
For an optimal study of polymerase activity in this cell line, it was important to rule out the 
presence of a cellular factor, which could differently modulate polymerase activities. This was 
assessed by the use of the minireplicon assay in CHODogSLAM cells, which showed a less 
efficient protein production than that setup in Vero cells (figure 15B). However, it was 
sufficient to highlight a higher polymerase activity for the wild-type virus strain compared to 
the adapted virus strain.  
Taken together all these experiments confirmed that the CHODogSLAM cells were the good 
in vitro model to compare A75/17 and A75/17-V CDV at an infection level. 
 
3.2.9 Infection of CHODogSLAM cells with A75/17 and A75/17-V CDV 
The CHODogSLAM cells allowed us for the first time to titrate the A75/17 wild-type virus 
obtained from lymphoid organs of experimentally infected dogs, which showed that the 
amount of infectious virus, of about 103 particles per gram of tissue, was surprisingly low in 
these organs. This finding obliged us to perform infection experiments at a very low m.o.i. 
due to the limited amount of material available to us. However, since both viruses were 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
NP a75 NP a75-V NPL A75/17 NPL A75/17-V
+
+
+
+
++
C
A
T
 c
on
ce
nt
ra
ti
on
 
(n
g/
m
l)
0.6
0.
0.4
1 432
P   A75/17
P   A75/17-V
L   A75/17
L   A75/17-V
B
* *
 72
titrated in the same cells, we are confident that a direct comparison between A75/17 and 
A75/17-V CDV was possible.  
A75/17-V CDV was demonstrated to have a lower polymerase activity compared to A75/17 
CDV in a synthetic system and this has to be determined at an infection level with the use of 
the CHODogSLAM cells. Infections will be characterized at early time points, from 12 to 48 
hours, in order to minimize the effect of virus budding and syncytium formation on 
polymerase activity. In fact, we have no clue whether polymerase activity could be modulated 
by the formation of fused cells and we could not exclude the importance of the M protein in 
the virus propagation. CHODogSLAM cells were infected at a m.o.i. of 0.0001 and infected 
cells were analyzed by immunocytochemistry (figure 16A) and Western blottings (figure 
16B).  
After 12 hours of infection, some visible foci were already detected for A75/17 CDV (figure 
16A, panel 2) and a single infected cell for A75/17-V CDV (panel 3). At 24 hours, A75/17 
CDV infection was characterized, not only by single infected cells but also by some small 
syncytia as shown in panel 5. In contrast, A75/17-V CDV only spread in single infected cells 
with a significant delay compared to A75/17 CDV. A75/17 CDV mainly spread through big 
syncytia (panel 8), while A75/17-V CDV through foci of infected cells with no obvious lack 
of syncytium formation (panel 9).  
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Figure 16. Multiplication of A75/17 and A75/17-V CDV in CHODogSLAM cells. CHODogSLAM 
cells were infected at a m.o.i.of 0.0001 with A75/17 and A75/17-V CDV for 12, 24 and 48 hours. N 
proteins were revealed by immunocytochemistry (A) and by Western blotting (B). 
 
The western blottings presented in figure 16B were done against the N protein and the 
tubuline, which served as an internal control and was constant for all the samples. A delay in 
protein expression level could also be noticed in cells infected with A75/17-V CDV as 
compared to cells infected with A75/17 CDV. After 12 hours of infection, no band was 
detected for both virus strains. After 24 hours, a strong band was observed for A75/17 CDV 
and a very faint one for A75/17-V CDV. This difference between the two virus strains was 
still present 48 hours post infection with a proportional increase in N protein production for 
A75/17 CDV and A75/17-V CDV strains in CHODogSLAM cells.  
 
3.2.10 Growth kinetics of A75/17 and A75/17-V CDV in CHODogSLAM cells 
Production of infectious viral particles was determined in CHODogSLAM cells at 12, 24 and 
48 hours post infection. Both extracellular and cell-associated viruses were titrated in 
CHODogSLAM cells. No virus was detected in the supernatant of cells infected with either 
virus strain (data not shown). A75/17 CDV formed infectious cell-associated viral particles 
after 24 and 48 hours of infection (figure 17). Very little virus was recovered from cells 
infected with A75/17-V CDV. Interestingly, there was a peak in cell-associated virus 
formation at 24 hours. The low level of infectious viral particles could then be observed from 
48 hours and was maintained in the long term infection (data not shown). 
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Figure 17. Growth kinetics of A75/17 and A75/17-V CDV in CHODogSLAM cells. CHODogSLAM 
cells were infected at a m.o.i. of 0.0001 for 12, 24 and 48 hours. Cell supernatant was stored at –70°C 
(cell free fraction). Cells were submitted to two cycles of freeze and thaw and centrifuged at 3000 rpm 
for 8 min at 4°C to remove cell debris; the supernatant is stored at –70°C (cell extract fraction). 
Dilutions of cell free and cell extract fractions were used to reinfect fresh CHODogSLAM cells for 24 
hours; the number of viral particles were counted after immmunocytochemistry. Only the cell extrat 
fraction is represented in this figure. 
 
Taken together, these results showed that in CHODogSLAM cells the less active polymerase 
of A75/17-V CDV had an impact not only on protein synthesis, but also on production of 
infectious particles and on kinetics of virus propagation. 
-20
0
20
40
60
80
100
12h p.i 24h p.i 48h
12h p.i 24h p.i
A75/17 A75/17 A75/17-VA75/17-V
100
50
0
vi
ra
l p
ar
tic
le
s 
/m
l
48h p.i
A75/17 A75/17-V
 75
3.3 EFFECT OF THE V AND C PROTEINS ON POLYMERASE ACTIVITY 
3.3.1 Increase of polymerase activity in the presence of the V protein 
Upon cell culture adaptation, the mutations located in the P gene, changing amino acids in the 
P protein, also changed the amino acid sequence of the V protein, but not of the C protein. 
The V protein produced by a cotranscriptional editing shared the amino terminal part with the 
P protein and exhibited a C terminal specific cysteine-rich region, giving rise to a shorter 
protein than the P protein. 
As the V proteins were different in amino acid sequence between A75/17 and A75/17-V 
CDV, it was interesting to test their impact on polymerase activity. The minireplicon assay 
was modified by cotransfecting plasmids encoding the wild-type, the adapted and the 
chimeric polymerases with V encoding plasmids of either A75/17 or A75/17-V CDV. In this 
assay, the V encoding plasmid of both strains was always cotransfected with its corresponding 
P encoding plasmid. 
 
The results are presented in figure 18. First, the effect of the V protein of A75/17-V CDV was 
tested on the low active polymerases constituted of the P protein of A75/17-V and the L 
protein of either A75/17 or A75/17-V CDV, which exhibited very low CAT concentrations as 
described before. In figure 17A, the addition of the V encoding plasmid increased 8-fold the 
polymerase activity of the adapted virus strain and about 4-fold the low active chimeric 
polymerase. The V encoding plasmid concentration of 50ng was chosen as the optimal 
concentration, although the same activating effect could already be observed at 25ng as well 
as at 100ng. 
 
Concerning the V protein of A75/17 CDV, the same activating effect could be observed on 
the wild-type and on the active chimeric polymerases as described in figure 18B, with a 4 fold 
increase of polymerase activity in both cases. However, in the context of comparing 
polymerase activities between the wild-type and the Vero cell-adapted strains, the addition of 
the V protein slightly decreased the difference in activity of the wild-type as compared to the 
adapted strain, the latter being 25-fold less active in the absence of V and only 10-fold less 
active in the presence of V. 
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Figure 18. Effect of the V protein on polymerase activity determined by minireplicon assay. (A) The 
expresssion plasmid encoding the V protein of A75/17-V was cotransfected with the genes encoding 
either the polymerase of A75/17-V or the low active chimeric polymerase. (B) The expresssion 
plasmid encoding the V protein of A75/17 was cotransfected with the genes encoding either the 
polymerase of A75/17 or the active chimeric polymerase. * p< 0.05. 
 
3.3.2 The V and C proteins have a complementary effect on polymerase activity 
In these minireplicon assays, the plasmid encoding the P protein allowed the expression of the 
P protein as well as the production of the C protein from another reading frame downstream 
the start codon of the P protein. It was thus interesting to study polymerase activity in the 
absence of the C protein and to see the true effect of the V protein. Toward this end, the AUG 
start codon of the C protein was mutated into an ACG in the P and the V expression plasmids. 
As the ACG can sometimes be used by the ribosome to start translation, a stop codon was 
introduced 14nt downstream to completely abolish C production. This stop codon insertion 
did not change P and V amino acid sequences. These plasmids were then used in minireplicon 
assays as presented in figure 19. 
 
The polymerase activity of the Vero cell-adapted strain was presented in figure 19A (columns 
3, 4 and 5) together with the low active chimeric polymerase (columns 6, 7 and 8). The 
abrogation of the C protein in the P expression plasmid of A75/17-V CDV drastically 
increased polymerase activity to a similar extent as the V protein did in the presence of the C 
protein. Interestingly, this new polymerase activity determined in the absence of C was 
unchanged by the addition of the V protein (columns 5 and 8). 
 
The activity of polymerases constituted of the P protein of A75/17 CDV was presented in 
figure 19B. In contrast to the P protein of A75/17-V, the abrogation of the C protein from the 
P expression plasmid of A75/17 CDV significantly decreased polymerase activity by a factor 
of 6. And, in this context, the addition of the V protein still increased polymerase activity but 
did not allow this polymerase to regain the basal activity determined for the wild-type strain 
in the presence of the N, P, C and L proteins. 
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Figure 19. Effect of the V and C proteins on polymerase activity determined by minireplicon assay. 
Expression plasmids encoding the P and V proteins were abrogated of the C protein expression and 
tested in this minireplicon assay. Polymerase activity of either A75/17-V and the low active chimeric 
polymerase (A) or A75/17 and the active chimeric polymerase (B) were tested. * p < 0.05. 
 
In tables 6A and 6B, all the results on polymerase activity are presented. In table 6A, the 
effect of the accessory V and C proteins on their respective polymerases is listed. The 
abrogation of the C protein has an activating effect on polymerase activity of A75/17-V CDV 
(15-fold increase) and an inhibitory effect on polymerase activity of A75/17 CDV (5-fold 
decrease). 
 
 
 
 
 
 
 
 
 
As determined by the minireplicon assay, the polymerase activity of A75/17 CDV is 25 fold 
higher than the one of A75/17-V CDV. This observation was confirmed in the presence of the 
M and the V proteins. However, in the absence of the C protein, the polymerase activity was 
reversed. Interestingly, the polymerase activity of the adapted virus strain became 2 to 4 fold 
higher than the polymerase activity of the wild-type virus strain in the absence of the C 
protein. 
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Table 6B. Comparison of polymerase activities of A75/17 and A75/17-V CDV
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3.3.3 Generation of a recombinant A75/17-V CDV knock out virus for the C protein 
The C protein was demonstrated to inhibit polymerase activity of A75/17-V CDV in a 
minireplicon assay. As in this assay, not all the viral proteins are present, a recombinant virus 
was produced from a cloned cDNA to determine whether the absence of the C protein still 
enhanced virus replication. The full length of A75/17-V CDV was constructed in our 
laboratory and the generation of recombinant viruses was setup. The P gene of the full length 
of A75/17-V CDV was mutated by eliminating the start codon of the C protein (AUG into 
ACG) and by introducing a stop codon without changing the P and V open reading frames.  
BSRT7/5 cells were transfected with the full length antigenome and the N, P and L expression 
plasmids of A75/17 CDV for 48 hours at 37°C to produce viral particles. As these cells are 
not permissive for A75/17-V CDV, they were cocultured after 2 days with Vero cells 
allowing the new viral particles to spread. After two cycles of freeze and thaw, the 
recombinant viruses were amplified in Vero cells for 5 days at 37°C, titrated and 
characterized. 
 
For the characterization, Vero cells were infected with the two recombinants, rA75/17-V and 
rA75/17-V P/C- at a m.o.i. of 0.1. Foci of infection were detected by immunocytochemistry 
(figure 20), proteins were analyzed by Western blotting (figure 21) and formation of viral 
particles by growth kinetics (figure 22). 
 
After 48 hours of infection small foci of infected cells could be detected for rA75/17-V and 
bigger ones for rA75/17-V P/C- (figure 19, panels 2 and 3). This difference was still present 
at 72h of infection, but was slightly weaker than that observed at 48h (panels 5 and 6). After 5 
days, a lot of infected cells were dying for both recombinant viruses and all adherent cells 
were infected (panels 8 and 9). 
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Figure 20. Immunocytochemistry of rA75/17-V and rA75/17-V P/C-. Vero cells were infected at a 
m.o.i of 0.1 with the recombinant viruses rA75/1-V and rA75/17-V P/C- for 48, 72 and 120 hours. 
 
In figure 21, Western blotting was done using the anti-N antibody. The tubuline, serving as an 
internal control, was similar for all conditions. There is a delay in protein production for 
A75/17-V CDV at 48 hours post infection, which was correlated with the number of infected 
cells observed by immunocytochemistry. However, protein production was almost equivalent 
after 72 hours of infection, reaching a plateau that was still observed after 5 days.  
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Figure 21. Western blots of rA75/17-V and rA75/17-V P/C-. Vero cells were infected at a m.o.i of 0.1 
with the recombinant viruses rA75/1-V and rA75/17-V P/C- for 48, 72 and 120 hours. 
 
Finally, the growth kinetics of both recombinant viruses confirmed the higher multiplication 
rate of the rA75/17-V P/C- at the level of cell-associated particles as well as at the level of 
particles in the supernatant of infected cells (figure 22A and 22B, respectively). The number 
of cell-associated particles was about one log higher than the free viral particles. The 
recombinant rA75/17-V had a delay of about one log compared to the rA75/17-V P/C- for the 
cell-associated fraction as well as in the number of free viral particles. This delay in viral 
particle formation was more important early in infection and was minimal from 4 days post 
infection. 
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Figure 22. Growth kinetics of rA75/17-V and rA75/17-V P/C- in Vero cells. Vero cells were infected 
at a m.o.i of 0.1 with the recombinant viruses rA75/1-V and rA75/17-V P/C- for 1, 2, 3, 4 and 5 days. 
The number of viral particles were determined for the cell free and cell-associated particles. 
 
In conclusion, we observed that the recombinant rA75/17-V P/C- virus exhibited a faster 
multiplication rate as shown at the protein level as well as in the formation of new viral 
particles. This confirmed the polymerase study with the minireplicon assay, in which the 
absence of the C protein increased polymerase activity of A75/17-V CDV. Unfortunately, the 
recovery of the wild-type A75/17 could not yet be done as the full length plasmid is under 
construct. Consequently, it did not allow us to study the activating effect of the C protein in 
the viral context of A75/17 CDV. 
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3.4 RAPID INCREASE OF INFECTIOUS VIRUS RELEASE UPON WILD-TYPE CANINE 
DISTEMPER VIRUS INFECTION OF PRIMARY DOG KERATINOCYTES 
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Introduction 
Canine distemper virus (CDV) is a negative-strand RNA virus which belongs to the 
Morbillivirus genus in the Paramyxoviridae family. Infection with these agents still causes 
high mortality epidemics in many different species, including domestic dogs. Naturally CDV 
infection results in systemic disease with involvement of the respiratory, gastrointestinal and 
central nervous systems (CNS) (3). Like measles, canine distemper is associated with 
profound short and long-term immune suppression, and much of the mortality is caused by 
secondary infection (39, 127). Direct infection of the CNS and neurological diseases are more 
common in young dogs than in older, and can occur either early after infection or 3 to 4 weeks 
later associated with the infection of oligodendrocytes and demyelination. Persistence of virus 
in neurons and epidermal cells of the feet leads to diseases known as old dog encephalitis and 
hard pad disease (7). CDV is known to replicate widely in a variety of epithelial and 
mesenchymal tissues (7). Immunocytochemistry of these tissues showed that the virus was 
detected in footpad epithelium and it was possible to use the biopsies of the footpad as a 
means of ante mortem diagnosis of infection (97). 
A75/17-CDV, a virulent wild type strain was isolated from a dog with spontaneous distemper 
and may be considered as the prototype virulent CDV. In primary dog brain cell culture 
(DBCC) this virus produces a non-cytolytic, persistent infection with very selective virus 
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spread via micro fusion between cell processes (237) characteristic of the in vivo situation in 
the central nervous system (227). Interestingly, the virus does not grow in cell lines unless it is 
adapted by many weeks of blind passaging (98). However, the virus may be propagated in 
cells expressing the SLAM receptor (190). Wild type strain A75/17-CDV establishes a 
persistent non-cytocidal infection in canine footpad and in primary dog keratinocytes 
immediately following inoculation (93, 94). 
In this study we compared the neurovirulent A75/17-CDV isolate and its derivate, which has 
been adapted to efficiently spread in canine footpad keratinocytes. Genome sequence 
comparison showed 4 amino acid differences located in the P, M and H proteins. Thus, the 
capacity of these viruses to infect various cell lines, their RNA polymerase activity as well as 
the fusion-inducing ability of their respective envelope glycoproteins was analyzed. The 
results suggest that the adaptation of the wild-type A75/17-CDV in primary dog keratinocytes 
rapidly select a variant, which produces large amount of viral particles. 
 
Material and methods 
Cell culture and virus.  
Primary dog footpad keratinocytes (PDK) were a gift of Andreas Zurbriggen (University of 
Bern). Cells were maintained in William’s E medium (Bioconcept) including 
antibiotic/antimytotic solution (Gibco BRL), 10% fetal bovine serum, L-glutamine 2mM 
(Bioconcept), 10-10 M cholera toxin (Sigma), and 10ng/ml of epidermal growth factor EGF 
(Sigma). Cells were incubated at 34°C in 5% CO2. Vero cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma) containing 10% foetal bovine serum, penicillin 
and streptomycin (Gibco) at 37°C in 5% CO2. Vero-DogSLAMtag cells were maintained in 
DMEM containing 10% foetal bovine serum, penicillin and streptomycin at 37°C in 5% CO2 
in the presence of 0.5 mg/ml of G418 (Promega). CHO-DogSLAMtag cells were maintained 
in DMEM/NUT.MIX :F12 (Gibco) supplemented with 10% FBS, 1X hypoxanthine (Gibco) 
and 0.5 mg/ml of G418 (Promega). The wild-type canine distemper virus, designated A75/17-
CDV was obtained from M. Appel, Cornell University, Ithaca, N-Y. The virus was grown in 
experimentally infected dogs. A homogenate of lymphoid organs was used for infection of 
cultured cell lines. The Keratinocyte-adapted CDV, designed A75/17-K, was obtained after 3 
passages of the wild-type virus in primary dog footpad keratinocytes. 
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Titration and infection.  
The titer of A75/17 and A75/17-K CDV was determined by limiting dilution of the viral stock 
in CHO-DogSLAMtag cells followed by immunohistochemical staining using a CDV-N-
specific monoclonal D110 antibody, as described previously (98). Primary dog footpad 
keratinocytes, Vero and Vero-dogSLAMtag cells were infected with A75/17 or A75/17-K 
CDV at an m.o.i of 0.0001. After 1h at 34°C and 37°C respectively, the inoculum was 
removed and the cells were incubated for different time points in medium containing 2% 
FBS. 
 
Sequencing of the A75/17-K virus.  
Total RNA was extracted from A75/17-K CDV infected canine footpad keratinocytes using 
the RNeasy kit (Qiagen). Regions spanning all genes were then reverse transcribed from viral 
genomic RNA using Superscript II (Invitrogen) reverse transcriptase (RT) and random 
primers. PCR amplification was performed using the Taq polymerase (Promega) with specific 
primers. Purified PCR fragments were directly subjected to DNA sequencing. To sequence 
the 3’ and 5’ ends of the genome, cDNA of both termini were synthesized by the RACE 
method (229), using the GeneRacer Kit (Invitrogen, Carlsbad, CA), and cloned into the 
plasmid pUC18. Several clones were sequenced. 
 
Virus growth.  
Primary dog footpad keratinocytes, Vero and Vero-dogSLAMtag cells at 80% confluency 
were infected at a m.o.i of 0.0001 for 2 hours at 34°C and 37°C respectively. Cell-free virus 
was prepared by clarifying cell supernatants by centrifugation at 1500 x g, and cell-associated 
virus was recovered by scraping the cells in 1 ml of Opti-MEM (Gibco) followed by two 
cycles of freeze-thaw. Samples were stored at -80°C and virus titers were determined by 
immuncytochemistry of infected CHO-dogSLAMtag cells, as described above. 
 
Construction of plasmids.  
The wild-type F and H genes termed is this study FWT and HWT respectively, and OP-CDV F 
gene, termed FOP were cloned into the eukaryotic expression vector pCI (Promega). 
The genes encoding the N, P and L proteins of A75/17-CDV were cloned in the eukaryotic 
expression plasmid pTM-1, as already described (170). The wild-type H and P expression 
plasmids were then mutated to obtain the sequence of the A75/17-K, by site directed 
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mutagenesis using the Quick Change Site Directed Mutagenesis kit (Stratagene). The 
resulting genes are termed Hk and Pk respectively, in this study. 
 
Minireplicon assay.  
Vero and Vero-dogSLAMtag cells were infected with recombinant MVA at a m.o.i of 1 at 
room temperature for 1 hour and transfected in 6-well culture dishes at a confluence of 100% 
with LipofectamineTM 2000 Reagent (Invitrogen) according to the manufacturer’s protocol. 
Transfections contained the following DNA: 600 ng of peGFP/CAT(+), 200 ng of pTM-N, 
200 ng of pTM-P from A75/17 and A75/17-K CDV, 50 ng of pTM-L and 150 ng of pCMV-
β-galactosidase. After 4 hours, the medium was replaced by DMEM 10% FBS. At 24 hours 
after transfection, the cells were lysed with 0.5 ml of lysis buffer contained in the CAT 
ELISA kit (Roche). 
 
Measurement of CAT and β-galactosidase.  
Cell lysates were diluted 100-fold and assayed for the presence of CAT and β-galactosidase. 
The β-galactosidase measurement was performed at 595 nm using 30µl of lysates, which was 
mixed with 150 µl of CPRG buffer (60 mM Na2HPO4 7H2O, 40 mM NaH2PO4, 10 mM KCl, 
1 mM MgSO4, 50 mM β-mercaptoethanol) and 20 µl of CPRG diluted at 4 mg ml-1 in H2O. 
An ELISA kit (Roche) was employed for CAT quantification according to the manufacturer’s 
instructions using 200 ul of lysate. Absorbances were read at 405 nm and normalized to the 
values of β-galactosidase. The normalized results were expressed as CAT concentration 
determined from a standard curve. 
 
Transfections.  
Primary dog footpad keratinocytes, Vero and Vero-dogSLAMtag cells, in 6-well plates at 
90% confluency, were transfected with 1 µg of pCI-FOP, pCI-FWT, pCI-HWT and pCI-Hk in 
different combinations, using LipofectamineTM 2000 (Gibco) according to the 
manufacturer’s protocol. Pictures of transfected cells were taken 24 hours after transfection 
with a microscope equipped with a DC 350FX digital camera (Leica). 
 
Western blotting.  
Proteins were extracted from cells, separated by reducing SDS-PAGE, blotted onto 
nitrocellulose membrane (Schleicher & Schuell BioScience) and detected with the 
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monoclonal antibody (mAb) D110 (98), anti-P (144), anti-L, anti-F, anti-M rabbit antiserum, 
and anti-M mAb (147).  
 
Results 
Growth comparison of A75/17 and A75/17-K viruses in primary dog keratinocytes.  
Immunocytochemistry of footpads of CDV infected dogs showed the presence of viral 
antigens in keratinocytes. Moreover, infection of this tissue is characterized by a persistent 
phenotype without syncytia formation and absence of inclusion bodies (93). Recently, it has 
been reported that A75/17-CDV infected primary dog keratinocytes (PDK) without prior cell-
adaptation (Gröne, A and Zurbriggen A., unpublished data). It appears therefore that PDK 
cells could be relevant for wild-type CDV isolation. Since only very limited amounts of 
A75/17-CDV obtained from lymphoid organs of infected dogs are available to us, we first 
amplified the virus by three additional passages in PDK. The resulting variant was designated 
A75/17-K and was characterized. 
Interestingly, infection of primary dog keratinocytes (PDK) with A75/17-CDV and A75/17-K 
induced a persistent infection with no obvious syncytia formation (Figure 23A). At 1.5 day 
after infection, only small clusters of individual infected cells were observed by 
immunocytochemistry with both strains. After 5 days of infection the immunostaining clearly 
demonstrated that A75/17-CDV hardly spread to the neighboring cells, while A75/17-K 
showed a very efficient dissemination throughout the cell monolayer (Figure 23A). These 
results prompted us first to analyze the growth kinetics of both A75/17 and A75/17-K viruses 
in PDK cells. Whereas no or very low levels of cell-free and cell-associated virus were 
detected after A75/17-CDV infection, A75/17-K efficiently produced both cell free and cell-
associated virus, typically reaching 0,5x106/ml of cell-associated infectious viruses 7-8 days 
after infection (Figure 23B).   
We next compared RNA as well as protein levels of both viruses by semi quantitative RT-
PCR and Western blot, respectively. At the RNA level, A75/17-K clearly showed a larger 
amount of transcripts, which could be correlated with the observed higher efficiency of 
dissemination in PDK cells (Figure 23C).  
Western blots revealed the presence of the N, M and F proteins for A75/17-K CDV and only 
the N and F proteins for A75/17 CDV (Figure 23D). To exclude that the failure to detect the 
M protein of the wild-type virus was not due to the inability of the antiserum to recognize the 
protein, both proteins were transiently expressed in PDK, which showed that the antiserum 
detected efficiently both proteins (data not shown). In order to investigate whether the wild-
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type M protein was less expressed in infected cells, increasing amounts of proteins extracted 
form A75/17 infected cells were loaded until the intensity of the band of the N protein was 
similar of the same intensity as for A75/17-K infected cells. Therefore, at equal N protein 
expression, the M protein of A75/17 was still absent. Taken together, these preliminary results 
clearly pointed out a deficiency of A75/17-CDV in the budding process as well as the 
capacity of A75/17-K to efficiently disseminate in PDK being associated with an increase in 
infectious virus production. 
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Figure 23. Characterization of A75/17 and A75/17-K infections in keratinocytes. (A) Kinetics of virus 
propagation. Infected cells were analyzed by immunocytochemistry after the indicated time points of 
infection using the monoclonal anti-N antibody D110. (B) Growth characteristics of A75/17 and 
A75/17-K in kerationocytes. At the indicated days, infected cells were lysed and cell-associated 
progeny virions were titrated in keratinocytes. Virus released into the supernatant was also titrated. The 
number of infected single cells was determined after staining the monolayer by immunocytochemistry 
using the monoclonal anti-N antibody D110. Virus titers are expressed as units of infection (UI). (C) 
RT-PCR analysis of RNA isolated from infected cells. After 7 days of infection, RNA was isolated 
from infected and non-infected cells (ni) and N, M, and F-specific transcripts were analyzed by RT-
PCR using specific primers. Control amplification reactions were performed in the absence of RT (-
RT). The L27 ribosomal RNA served as internal standard. M, molecular size markers. (D) Western blot 
analysis. After 7 days of infection, cells were lysed and proteins were separated by polyacrylamide gel 
electrophoresis, transferred to membranes and probed with the monoclonal antibody D110 directed 
against the N protein, the monoclonal antibody X1-6 directed against the N protein, and a monospecific 
rabbit antiserum directed against the F protein. Protein extracts from non-infected cells (ni) served as 
controls. The position of molecular size markers are indicated at the left. 
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The keratinocyte-adapted virus presents different host cell specificities.  
In order to characterize A75/17-K, the cell tropism of both viruses were compared in different 
cell lines. Vero cells were first tested for infection with A75/17-K CDV leading to an efficient 
spred characterized with a persistent phenotype. As the wild-type A75/17-CDV is unable to 
replicate to detectable levels in Vero cells (98, 170), Vero cells stably expressing the canine 
SLAM receptor were established allowing the induction of a cytopathic effect (Figure 24A). 
Moreover, in VeroDogSLAM cells no difference betweem A75/17 and A75/17-K CDV is 
seen, since both viruses induced the formation of large syncytia (Figure 24A). 
Growth kinetics of A75/17 and A75/17-K CDV strains were next examined. In Vero cells, 
despite the fact that A75/17-K induced a persistent infection, production of both cell-
associated and cell-free viruses was observed (Figure 24C). After infection of A75/17-K in 
VeroDogSLAM cells, again both cell-free and cell-associate viruses were efficiently 
produced. In contrast, no infectious virus was recovered in the supernatant of A75/17-CDV 
VeroDogSLAM infected cells, although viral particles associated with the plasma membrane 
were detected, typically reaching a plateau three days after infection (Figure 24B). Moreover, 
it appeared that the cell-associated viruses were approximatively 1 log lower at day 3 as 
compared to the one of A75/17-K CDV (Figure 24B). 
Finally, cell entry efficiency in different cells was analyzed. CHODogSLAM cells were the 
first cell line to be tested as they enabled the fomation of big syncytia by both virus strains. 
The other cell lines were PDK, Vero and VeroDogSLAM cells and were infected at the same 
m.o.i. as determined in CHODogSLAM cells. Interestingly, A75/17-K seemed to enter PDK 
cells slightly but significantly more efficiently than the wild-type virus. This difference was 
even more pronounced in VeroDogSLAM cells, where A75/17-CDV showed a reduction in 
the titre of about 1 log as compared to A75/17-K (Figure 25C). As stipulated above, in Vero 
cells only A75/17-K was able to replicate (Figure 24C). 
Taken together these results first suggest that A75/17-K acquired the ability to bind a yet 
unknown receptor in Vero cells. Second, membrane fusion appeared to enhance virus release 
for the wild-type virus. It did not show any infectious virus production in persistently infected 
PDK cells, although it did so in VeroDogSLAM cells, where CPE was induced. Finally, it 
appeared that A75/17-K entered all cell types more efficiently. 
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Figure 24. Characterization of A75/17 and A75/17-K infections in keratinocytes, Vero and Vero-
dogSLAMtag cells. (A) Phenotype of infection in the indicated cell lines. At the indicated times of 
infection, infected cells were analyzed by immunocytochemistry using the monoclonal anti-N antibody 
D110. Non-infected cells (ni) served as controls. (B) Kinetics of virus propagation in Vero-
dogSLAMtag cells. At the indicated time points, virus in the supernatant and cell-associated virus was 
titrated in CHO-dogSLAMtag cells. The number of infected single cells was determined after staining 
the cells by immunocytochemistry using the monoclonal anti-N antibody D110. Virus titers are 
expressed as units of infection (UI). (C) Propagation of A75/17-K in Vero cells. At the indicated time 
points, virus in the supernatant and cell-associated virus was titrated in CHO-dogSLAMtag cells. The 
number of infected single cells was determined after staining the cells by immunocytochemistry using 
the monoclonal anti-N antibody D110. Virus titers are expressed as units of infection (UI). (D) Virus 
entry in different cell lines. One hundred units of infection of A75/17 and A75/17-K virus, previously 
titrated in CHO-dogSLAMtag cells were used to infect the indicated cells lines. After 24 hours, 
infected cells were analyzed by immunocytochemistry using the monoclonal anti-N antibody D110. 
The number of single infected cells determined in 2 independent experiments, as well as the standard 
deviation, is shown.  
 
Nucleotide and amino acid sequence comparison between A75/17 and A75/17-K. To 
characterize the genetic differences accounting for the increase of virus release and spread 
between the two strains, we sequenced their entire genomes. Comparison of the two genomes 
revealed that the total length of 15960 nucleotides and the overall organization were identical. 
Only five nucleotide differences were found. Three of them resulted in amino acid changes in 
the P, V and C proteins, in the M protein as well as in the H protein (Table 7). Other genome 
regions including the leader, trailer, transcription start and stops signals, intergenic sequences 
and non-coding regions of all six genes remained unchanged between the two viruses. 
However, it is important to note that for each mutated nucleotide we observed heterogeneity 
in multiple cDNAs obtained from infected cells. Therefore, at least 10 clones were sequenced 
for each mutations and the percentage of changes is represented in Table 1. Thus, this 
suggests that the stock of the adapted virus obtained after three passages in PDK likely 
represents a heterogeneous virus population.    
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Mutation in the P protein influences polymerase activity.  
We considered the possibility that the amino acid change in the P protein can influence the 
RNA polymerase activity. In order to study polymerase activity of both viruses, a 
minireplicon assay (Zweifel C., unpublished data) was used to compare polymerase of both 
viruses in Vero and VeroDogSLAM cells. (Figure 25A and B). The negative controls 
constituted of peGFP/CAT(+) together with plasmids encoding the N and P proteins, but 
lacking the plasmid encoding the L protein, showed only low CAT concentrations in both cell 
lines. In the presence of N, P and L, CAT concentrations of about 6.8 ng/ml was obtained in 
Vero cells transfected with the wild-type polymerase genes, whereas in the case of the PDK-
adapted polymerase genes, only 3.5 ng/ml was detected (Figure 25A). The same pattern was 
obtained in Vero-dogSLAMtag cells (Figure 25B). These results suggest that the RNA 
polymerase of the wild type virus is more active than the polymerase of the keratinocyte-
adapted virus. 
In order to rule out the possibility that the observed differences in polymerase activity were 
due to different expression levels of the N, P and L proteins, western blots were performed. 
The results showed that all proteins were expressed in similar amounts in transfected cells 
(Figure 25C) confirming that the RNA polymerase of the keratinocyte-adapted virus has a 
lower activity. 
Table 7. Comparison of nucleotide and deduced amino acid sequences between A75/17 and 
A75/17-K CDV
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Figure 25. Polymerase activity of A75/17 and of A75/17-K CDV. (A,B) Vero and Vero-dogSLAMtag 
cells were first infected with MVA, then transfected with pCMV β−gal, peGFP/CAT(+), pTM-N and 
the indicated combinations of plasmids encoding the A75/17-CDV or A75/17-K polymerase. 
Experiments were preformed in triplicate. Mean values and standard deviations are indicated. (C) 
Western blot analysis of cells transfected with the indicated plasmids. 
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Functional comparisons of the A75/17 and A75/17-K envelope glycoprotein. Although the 
F protein is the direct mediator of cell fusion, coexpression of the receptor binding H protein 
is required for cell fusion (203, 230). Nucleotide sequencing revealed no difference in either 
the coding or noncoding region of the F gene, but identified two nucleotide changes located 
both in the cytoplasmic tail of the H predicted amino acid sequence (Table 7). While one 
mutation was silent (L25L), the second showed that leucine at position 23 was changed into a 
proline (L23P).  
We therefore wished to investigate whether the H proteins of the two strains have different 
fusion-promoting ability. The mutation L23P was introduced by site directed mutagenesis in 
the wild-type H expression plasmid (43) and cell-to-cell fusion was analysed using a 
transient-expression system. Both H genes were cotransfected with either the wild-type F 
gene (which is identical in A75/17 and A75/17-K) or the F gene of the vaccine Onderstepoort 
CDV strain (FOP) in three different cell lines. As we previously showed that FOP was 
intrinsically more fusogenic than the one of the wild-type (Plattet P. et al, submitted), we 
therefore expected to easily detect any differences in the fusion-support function of the H 
protein.  
In primary dog keratinocytes transfected with the Hk encoding plasmid, syncytia were 
observed and this independently of the origin of the F encoding plasmid cotransfected (Figure 
26A).  In contrast, PDK expressing HWT showed CPE only in the presence of the FOP protein 
(Figure 26A). In VeroDogSLAM cells, all the combinations induced efficient cell-to-cell 
fusion (Figure 26C). Interestingly, in Vero cells and consistent with our previous 
observations, combinations including HWT never showed any CPE (Figure 26B). However, 
few syncytia were repeatedly observed when Hk was in combination with the highly 
fusogenic FOP protein (Figure 26). Taken together, these results suggest that the L23P 
mutation in the cytoplasmic tail of the Hk protein increases its affinity to bind to a plasma 
membrane bound receptor present in PDK and in Vero cells. 
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Figure 26. Transfection experiments in different cell lines. The F gene of A75/17 (FWT) or of OP-CDV 
(FOP) was co-transfected together with the H gene of A75/17 (HWT) or the H gene of the keratinocyte-
adapted virus (Hk) in the indicated cell lines. Cytopathic effects were observed at 24 hours post 
transfection by phase contrast microscopy. 
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CDV infection of canine footpads can result in the so-called hard pad disease, characterized 
by proliferation of footpad keratinocytes. Interestingly, recent observations showed that the 
wild-type A75/17-CDV can infect primary dog keratinocytes without prior cell-adaptation. 
Thus, we wished to further investigate whether these cells could be a relevant model for wild-
type CDV isolation. Our preliminary results pointed out that only three passages lead to a 
virus, which replicated efficiently in these cells. Genome comparison showed three mutations 
in the P, M and H genes changing the P, V, C, M and H proteins. However, these mutations 
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were not completely fixed, as demonstrated by the sequencing of at least 10 cDNA clones 
obtained from infected cells. Genomes of RNA viruses are thus heterogeneous (58, 65, 202), 
and it was proposed that this heterogeneity contributes to the efficient infection of multiple 
tissues (13, 151). We believe that information on the sequence of such a virus would give new 
insights in quasispecies existing in vivo. To investigate the role of these variants, we are 
currently cloning the full-length genome cDNA of the wild-type A75/17 strain. Mutations 
will be introduced in the backbone of the virulent virus, and recombinant viruses will be 
generated and analyzed. 
A75/17-CDV was obtained from thymus of infected dogs and was previously studied in dog 
brain cell culture (DBCC), where it produces a persistent infection and releases progeny 
viruses in the supernatant of infected cells. However, it is important to underline that the titer 
of released viruses barely exceeded 1x102/ml. Moreover, virus was released only 20 days 
after infection of DBCC, suggesting that the production of variant viruses could be the reason. 
Therefore, the situation seems to be very close to the phenotype observed in PDK cells. 
Indeed, the phenotype of infection was shown to be persistent also in PDK, and no or very 
limited amounts of infectious viruses were released. However, three passages in PDK cells 
lead to a more efficient dissemination, which was shown to be associated with an increase of 
infectious virus production. By genome sequencing of the PDK-adapted virus (A75/17-K), we 
next showed that the three mutations in the P, M and H proteins were the cause of this gain of 
function. However, whether the A75/17-K virus retained virulence in dogs remain to be 
determined.  
It is important to note that the difference in the P protein, which was shown to affect 
polymerase activity, did also change the V and C proteins. The effect of these proteins could 
have a major importance in virus pathogenesis and have to be extensively studied.  
Concerning the presence of a CDV receptor in PDK, the only known receptor for CDV is 
SLAM, a molecule restricted to activated T and B lymphocytes, immature thymocytes, 
mature dendritic cells and activated monocytes. Any attempt to detect the presence of SLAM 
in PDK failed (Rivals J.P., personal communication) suggesting the presence of an alternative 
receptor present in dogs. Studies to identify this membrane-bound molecule are underway. 
Nevertheless, it appears that the receptor in PDK does not allow the wild-type virus to induce 
syncytia, in contrast to SLAM. Therefore, we suggest that the affinity of the wild-type virus to 
the PDK receptor is lower than that for SLAM, which would in turn be a part of the 
explanation for the persistent infection observed in these cells.  Moreover, we clearly showed 
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a role of the wild-type F protein in determining a low cytopathic effect, which is the case in 
PDK. 
We showed that A75/17-K entered cells and induced cell-to-cell fusion more efficiently than 
the wild-type virus. As demonstrated by the transient expression system, the L23P mutation in 
the cytoplasmic tail of the Hk protein enhanced its fusion-promoting function. It is tempting to 
hypothesize that the mutation could influence the protein structure. Due to the lack of 
monoclonal antibodies directed against the H protein of CDV, it is difficult to confirm this 
hypothesis. Therefore, production of such antibodies would be of great interest. In addition, 
we showed that the cell entry was also enhanced in A75/17-K as compared to the wild-type 
and this in all cell types so far tested. Since cell-to-cell fusion is close, but not identical to the 
virus-cell fusion process, the relevance of the H protein in cell entry has to be determined. As 
stipulated above, construction of the full-length genome clone of A75/17-CDV is in progress 
and the introduction of the L23P mutation in the backbone of the virulent virus would be very 
interesting. It would probably confirm any role of the H protein in modulating cell entry 
efficiency, as well as its role in syncytia formation.  
The more efficient production of infectious viruses with A75/17-K could be attributed to the 
M protein , which has been described as being the driving force in the budding process. 
Sequencing showed that the proline at position 33 was changed into a serine (P33S). Since 
proline is known to be important for secondary structure of proteins, the M protein of A75/17 
and A75/17-K might have different conformations, which could explain the observed 
increased production of infectious virus. On the other hand, motif known as "late motif 
domain" were demonstrated to play a crucial role in the budding process. However, the 
typical late budding motif is not found in the CDV M protein, and the P33S mutation is not 
present in a similar region of the Mk protein.  
We showed that wild-type adaptation to Vero cells was independent of both the F and H 
proteins, since no mutation was found in these proteins when compared to the one of the wild-
type virus. Moreover, whereas the Vero cell-adapted virus was able to efficiently enter and 
replicate in Vero cells, the wild-type virus hardly infects these cells. We therefore suggest a 
role of the M protein in modulating the viral tropism. Therefore the P33S mutation found in 
the Mk protein could also affect the host cell specificity of the A75/17-K variant. In order to 
investigate the role of the Mk protein in the budding process and the viral tropism, we plan to 
generate recombinant wild-type viruses with swapped M proteins. 
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3.4.2 Personal contribution to this article 
In this article as a third author, I contributed in determining the role of the P protein on 
polymerase activity. I also created the expression plasmid encoding the P A75/17-K CDV by 
site directed mutagenesis of the pTM-P A75/17. I also provided the conditions for the 
minigenome assay to test polymerase activity and all the plasmids for that assay. 
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4. DISCUSSION 
4.1 CELL CULTURE ADAPTATION 
Monkey kidney cell lines (Vero and CV1 cells) were frequently used for measles virus 
isolation and propagation before the EBV-transformed marmoset B-lymphoblastoid cell line 
B95-8 and its derivatives, such as B95a became available and before the SLAM receptor was 
known to be the receptor for measles virus. Thus, measles wild-type isolates were frequently 
adapted to growth in Vero cells, which has also been done for canine distemper virus. 
Cell culture adaptation of paramyxoviruses is frequently associated with changes in the 
attachment proteins (179), enabling the virus to enter cells via alternative receptors (142). 
Another mechanism of adaptation involves mutations in the P/V/C and L genes suggesting the 
importance of amino acid changes in the polymerase and accessory proteins for the MV 
attenuation and cell tropism (211, 215).  
Adaptation of A75/17 CDV in Vero cells involved only seven mutations in the P/V/C, M and 
L genes but none in the F and H genes, changing the amino acid sequences of the P, V, M and 
L proteins, but not of the C protein (170). In addition, no change was revealed in the cis-
acting regulatory regions for viral transcription and replication, including the leader, trailer, 
stop-restart, and intergenic sequences. Moreover, no change was found in the non coding 
regions of all six CDV genes, which might be involved in translational regulation. Thus, the 
identified nucleotide changes were all within the ORFs and resulted in amino acid changes. 
The sequence data was therefore highly informative in that the phenotypic differences both in 
vitro and in vivo between the two virus strains were attributable to the changes in viral 
proteins.  
 
In this thesis, the effects of the mutations in the P and L proteins were first examined. This 
showed that the resulting amino acid changes affect polymerase activity. More precisely, 
these mutations lead to a decrease in polymerase activity, both at the level of transcription and 
replication upon cell culture adaptation. This was assessed in Vero cells as well as in 
CHODogSLAM cells, in which both virus strains were able to enter through the SLAM 
receptor with the same efficiency. We currently have no clues as to why cell culture 
adaptation of the wild-type virus was accompanied by, or even required a reduction of 
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polymerase activity but this finding might explain the in vivo attenuation of A75/17-V CDV 
(98). 
The in vivo attenuation paralleling the decrease of replication and syncytium-inducing 
capabilities has already been observed for measles virus (wild-type 9301B strain), which was 
adapted to Vero cells after 10 passages (Vero cell-adapted 9301V strain). This adaptation lead 
to different mutations located in the P/V/C, H and L genes. A marmoset B-cell line (B95a) 
allowed the multiplication of both virus strains through the use of the CD46 receptor or the 
SLAM receptor (211) and showed that the adapted virus strain had a decreased transcription 
activity as compared to the wild-type virus. These results suggested that measles virus 
attenuation through adaptation to growth in Vero cells could involve the impediment of 
transcription, which appeared to be caused by a few amino acid changes in the polymerase 
and/or the accessory V and C proteins (211).  
CDV adaptation to growth in Vero cells is accompanied by a decrease in its capacity to 
replicate, to form new infectious particles and to induce syncytia in CHODogSLAM cells. 
Thus, these decreases are probably good in vitro markers for CDV attenuation in vivo. 
Another study reported the importance of mutations in the P/V/C and M genes for the cell 
tropism and pathogenicity of measles virus through the adaptation of a virus obtained from an 
acute measles patient. This strain was either isolated in B95a cells or in Vero cells. The virus 
grown in the latter cells did no longer cause any clinical signs in infected monkeys any more 
(215). 
Interestingly, most of the studies on virus adaptation revealed that the H protein was not an 
important factor in determining cell tropism. On the one hand, it was reported that adaptation 
of a virus in a specific cell line did not require mutations in the H gene (215) and on the other 
hand, when mutations occurred, they did not seem to be of crucial importance in cell fusion 
(211). A recent study extended that changes in the H protein of morbillivirus are not required 
for adaptation to Vero cells (158). Consequently, Vero cells apparently express one or several 
receptors that can bind the H proteins of wild-type morbilliviruses.  
 
4.2 RECEPTORS OF CANINE DISTEMPER VIRUS 
Up to date, two morbillivirus receptors have been identified, CD46 and CD150 also known as 
SLAM (219). In Vero cells, CD46 can serve as a receptor for laboratory strains of MV (140, 
155), whereas no evidence for a role of CD46 as a receptor for CDV or rinderpest virus has 
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been found. The adapted A75/17-V CDV has been tested for CD46 usage by blocking Vero 
cells with an anti-CD46 antibody and its entry was not inhibited suggesting that the adaptation 
of the wild-type A75/17 CDV in Vero cells was not due to the recognition of the CD46 
receptor (data not shown).  
A recent study by Tatsuo et al. described CD150 as a receptor used by all wild-type 
morbilliviruses (219). The expression of CD150 seems to be restricted to a limited subset of 
cells, which can be linked to the immunosuppression induced by measles virus infection 
(218). This receptor has never been found in Vero cells, neither at the protein, nor at the 
mRNA level. Thus, receptors on Vero cells that bind the H proteins of wild-type 
morbilliviruses do not appear to be CD46 or CD150. The CD9 receptor, which could be 
another candidate for canine distemper virus, has been shown to be a receptor for this virus, 
however, it is only used for virus propagation and not for virus entry (185). Consequently, this 
points out the existence of one or more unidentified receptors for wild-type morbilliviruses, 
expressed in Vero cells. 
In this work, CD150 also known as the SLAM receptor has been shown to be used not only 
by a wild-type canine distemper virus, but also by a cell-culture adapted virus, the A75/17-V 
strain. Transfection of this receptor in any cell line so far tested induced the formation of big 
syncytia following infection with the wild-type A75/17 CDV. In addition, the establishment 
of CHODG44 cells stably expressing the canine SLAM receptor (CHODogSLAM cells) 
allowed us for the first time to titrate the A75/17 wild-type virus obtained from lymphoid 
organs of experimentally infected dogs. This showed that the amount of infectious virus, of 
about 103 particles per gram of tissue, was surprisingly low in these organs. This finding 
obliged us to perform infection experiments at a very low multiplicity of infection (m.o.i). due 
to the limited amount of material available to us. 
The Vero cell-adapted virus strain was also titrated in CHODogSLAM cells in order to make 
a direct comparison with the wild-type strain and was thus used at the same m.o.i. of 0.0001.  
Therefore, in the presence of the SLAM receptor, the adapted virus strain could induce few 
syncytia as compared to the wild-type strain.  
The presence and the size of syncytia seemed to be dependent not only on the concentration 
of the SLAM receptor at the cell surface, but also on the amount of virus used for infection. 
We found that by increasing the m.o.i. of A75/17-V in CHODogSLAM cells, the numbers of 
syncytia proportionnaly increased and the number of single infected cells decreased (data not 
shown). By increasing the m.o.i., it is suggested that more viral particles are provided for 
infection and consequently, more viral proteins are produced in the cytoplasm of the infected 
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cells. Syncytium formation of CDV and measles virus requires the concerted activities of both 
the H and F glycoproteins, and the induction of syncytia certainly depends on the 
concentration of the F and H proteins at the cell surface once a cell has been infected. Thus, 
by increasing the m.o.i., more F and H proteins could be produced and translocated to the 
plasma membrane of infected cells, inducing more fusion between neighbouring cells and 
consequently formation of more syncytia. The mechanism used by a virus to increase the 
production of viral proteins, including the F and H proteins, is by increasing its transcription. 
Consequently, this observation could indirectly suggest an association between the replication 
rate of the virus and the viral capability to induce syncytium formation in the presence of the 
SLAM receptor. In addition, this perfectly fits with the more active polymerase of A75/17 
which induces more syncytia than A75/17-V. 
 
As mentioned above, the CHODogSLAM cells could represent a good in vitro model for 
comparative studies of the wild-type A75/17 and the adapted A75/17-V viruses in order to 
determine the molecular mechanisms underlying CDV pathogenesis. The SLAM receptor has 
been shown to have an important function in the immunosuppressive effect caused by measles 
virus (218) and could probably also be relevant for CDV infection of lymphoid tissues. The 
growth kinetics of CDV viruses in CHODogSLAM cells showed a very particular curve, 
specific to the presence of the SLAM receptor and not dependent on the virus strain used for 
infection. First, no progeny was released into the cell culture medium suggesting that the 
SLAM receptor prevents virus budding. SLAM molecules at the surface of neighbouring cells 
may interact with each others, making SLAM-SLAM associations and allowing viruses to 
spread in a cell-to-cell manner.  The cell-associated viruses were titrated and peaked at 36 
hours post infection (p.i.) (data not shown) and decreased progressively to reach a low plateau 
from 72 hours p.i.. Then a very small amount of infectious viral particles was present after 72 
hours of infection and at 36 hours p.i, representing the point when the maximal number of 
viral particles was released, the amount of virus did not exceed the input, suggesting the 
presence of a very poor virus amplification. Consequently, the CHODogSLAM cells could 
not be used for virus isolation, as it was planned.  
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4.3 RNA POLMYERASE OF CANINE DISTEMPER VIRUS 
As it has been very surprinsingly demonstrated in this work, adaptation of the wild-type 
A75/17 CDV in Vero cells gave rise to an attenuated virus with a decreased polymerase 
activity. This decrease in polymerase activity was really not what has been expected at the 
beginning of the work considering the fact that a lower polymerase activity is accompanied by 
a better multiplication efficiency in Vero cells. However, this result has been many times 
confirmed and could be truly taken into account. 
This decrease was attributed to the mutations in the P protein, and could be due to the only 
conserved amino acid changed at position 194. This change concerned a leucine that was 
mutated to a proline residue. Since proline is known to be important for secondary structure of 
proteins, the P proteins of A75/17 and A75/17-V CDV might have different conformations, 
which could explain the observed reduction in polymerase activity of the latter virus strain. In 
the L protein, the conserved basic glutamine in the wild-type strain was mutated into an acidic 
glutamate, however this change did not affect polymerase activity as shown by the activities 
of the chimeric polymerases. 
In the literature, the catalytic subunit of the polymerase of Paramyxoviridae has been 
attributed to the L protein and mutations in this protein have been reported to modulate 
polymerase functions. However, in the case of A75/17-V CDV, the single mutation of the L 
protein, which is located between domain V and VI, did not have any impact on polymerase 
activity. 
The P protein of Paramyxoviridae was reported to play the role of a chaperone protein, first 
by helping the nucleocapsid proteins to assemble correctly around the RNA and second by 
associating the polymerase to the nucleocapsid making the polymerase functional. These 
associations were mapped to different regions on the P protein: for the Paramyxoviridae, the 
unassembled N protein interact with the N-terminal part of the P protein, and the RNA-
assembled N proteins with the C terminal part as well as with the L protein, but this has never 
been demonstrated for canine distemper virus. Thus, the P protein is the central element of the 
viral replication machinery and although it does not itself confer activity to the polymerase 
complex, it enables the complex to function correctly.  
In the P protein, the conserved amino acid was suggested to induce a conformational change 
of the protein between the wild-type and the attenuated virus, which could influence 
interactions with the N and L proteins. Regions of the N and P proteins implicated in their 
interactions have been mapped to the N terminal part of the P protein, implicating only the 
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non-associated N proteins. In fact, these experiments were done by transfecting expression 
plasmids encoding the N and P proteins without the RNA template, thus mimicking the 
interaction of the free N proteins not yet assembled on the viral RNA with the P protein. This 
interaction was reported to be essential for a correct association and formation of the viral 
nucleocapsid.  
The N-terminal part of the P protein associating with the free N proteins was mapped to the 
first 60 amino acids. The conserved residue 194 is located outside of this region, but could 
still have an impact on N-P interactions by changing for example the affinity of the 
association by the introduction of a hinge in the P protein. This conformational change could 
therefore have an indirect impact on polymerase activity by modulating P protein interactions 
with the N and L proteins. In any case, this change did not abolish N-P interaction, which was 
confirmed by the coimmunoprecipitation of the N with the P protein of A75/17 CDV resulting 
in a similar pattern as with the P protein of A75/17-V CDV (data not shown).  
 
The wild-type virus has also been adapted to primary dog keratinocytes, which allowed 
multiplication in Vero cells to higher titers than the Vero cell-adapted virus itself. This virus 
was under a high selective pressure where five mutations occurred after only three passages in 
the dog primary keratinocytes: one in the P/V/C gene changing the P, V and C proteins, two 
in the M gene and two in the H gene. Two mutations were silent, one in the M protein and one 
in the H protein. As observed upon Vero cell culture adaptation, the polymerase activity of 
the wild-type virus is decreased after passages in primary dog keratinocytes. However, in this 
case, it does not seem to be the consequence of a conformational change of the P protein, but 
due to the mutation of a serine to an asparagine. The elimination of a potential 
phosphorylation site could thus have an impact on polymerase activity as it has been reported 
that phosphorylation of the P protein is essential for its function. 
 
4.4 ROLE OF THE M PROTEIN IN VIRUS ADAPTATION 
Interestingly, the adaptation of the wild-type canine distemper virus decreased polymerase 
activity and resulted in a higher multiplication rate of the virus in the cells used for virus 
adaptation. However, only the mutations in the P proteins were so far considered for 
determining polymerase activity, which is not sufficient. Indeed, mutations in the M proteins 
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were induced during adaptation, which could be of major interest in understanding virus 
pathogenesis. 
The M protein is known to interact not only with the nucleocapsid proteins, but also to make 
contact with the cytoplasmic tails of the F and H proteins (36). These interactions could 
influence on the one hand viral transcription and on the other hand virus budding. Viral 
transcription was shown not to be influenced by the M protein of either the wild-type or the 
Vero cell-adapted CDV viruses. Concerning virus budding, it has not yet been extensively 
studied and the use of recombinant viruses expressing different M proteins will provide 
interesting information. It has been reported that the M protein of measles virus modulates the 
fusogenic capacity of the viral envelope glycoproteins (200) by interacting with the 
cytoplasmic tails of the F and H glycoproteins. One hypothesis for the adaptation of wild-type 
canine distemper virus in Vero cells as well as in PDK is that the mutations in the M protein 
induce a different interaction with the cytoplasmic tails. This could influence viral 
fusogenicity, allowing a more efficient cell entry either by increasing receptor affinity of the 
H protein or by increasing fusion process via the F protein. This needs to be studied in more 
details. 
Recombinant knock-out measles viruses for the M protein were reported to be more 
fusogenic, inducing more cell-cell fusion and to yield significantly lower virus titers (36). For 
Sendai virus, a M knock-out virus also lost the ability to produce progeny and gained cell-to-
cell spreading via a mechanism dependent on the activation of the fusion protein (115). In 
vivo, measles viruses lacking the M gene lost acute pathogenicity but were shown to penetrate 
more deeply into the brain than standard recombinant measles viruses expressing the M 
protein (36). Abrogation of M function dramatically alters the assembly of measles virus, and 
is likely to be a factor responsible for subacute sclerosing panencephalitis (SSPE), a chronic 
disorder associated with defective measles virus genomes (21), which is closely related to the 
persistent central nervous system infection of CDV.  
Interestingly, the wild-type A75/17 CDV has a very high syncytium-inducing capability, 
higher than that of A75/17-V CDV, which could no longer enter the central nervous system. 
In addition, growth kinetics in CHODogSLAM and VeroDogSLAM cells showed a defect in 
virus particle formation, which could thus be related to a defect in M protein expression. After 
infection with A75/17, the presence of the M protein was tested many times by western 
blotting but was very difficult to detect. Taken together, this suggests a possible lack of M 
expression for A75/17, in contrast to both cell-adapted viruses, A75/17-V and A75/17-K for 
which the M protein was produced in large amounts. The absence in M protein production 
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could also be correlated with the persistent infection of the dog’s central nervous system, 
characteristic of the prototype virulent A75/17 CDV. 
In conclusion, adaptation of canine distemper virus in cell culture lead to a different cell 
tropism which could be due to either mutations in the M protein or to mutations in both the M 
protein and the cytoplasmic tail of the H protein, showing an important role of these proteins 
in virus budding and cell-to-cell fusion. This is consistent with the litterature where the 
majority of studies on virus budding concentrate on the cytoplasmic tails of the glycoproteins 
and their interaction with the matrix protein, and surprisingly do not address the role of the 
extracellular region of the glycoproteins. 
 
4.5 INTERFERON SENSITIVITY OF CANINE DISTEMPER VIRUS 
Recently, the wild-type M protein of vesicular stomatitis virus has been shown to suppress 
interferon gene expression through the general inhibition of host RNA and protein synthesis 
(1). Interactions with the interferon system were mostly attributed to the accessory V and C 
proteins of paramyxoviruses, counteracting the antiviral state put in place by the host immune 
system. Altogether, this points out a crucial importance of the interferon system in the viral 
pathogenesis. 
Vero cells, which were used to adapt the wild-type A75/17, are defective in interferon 
production. The Vero cell-adapted virus is thus able to replicate efficiently in these cells, but 
lost its in vivo pathogenicity. This raises the question whether this virus lost its capacity to 
counteract the antiviral response leading to a virus, which will be eliminated in the dog and 
which consequently could not be detected in the central nervous system. If this was the case, 
this could be attributed to the mutations in the V protein.  
The interferon sensitivity of the adapted A75/17-V strain was also tested in CV1 cells, which 
are similar to Vero cells, but do not have a defect in interferon production. The replication and 
propagation of this virus was drastically decreased in these cells (data not shown), suggesting 
an inhibition of virus growth by the interferon system. Unfortunately, experiments with 
A75/17 could not be done as this virus does not replicate in these cell lines. 
Concerning the keratinocyte adapted virus, it also contains mutations in the accessory V and 
C proteins, which could then influence pathogenicity and sensitivity to the interferon system. 
Although it is not yet known whether this adaptation attenuated the virus in vivo, one may 
speculate that this virus lost its pathogenicity. Indeed, both adapted viruses have a decreased 
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polymerase activity and have mutations in the accessory proteins as well as in the matrix 
protein. 
 
4.6 THE ROLE OF THE ACCESSORY PROTEINS IN VIRUS ADAPTATION 
The V and C proteins have been extensively studied for the Vero cell-adapted A75/17-V CDV 
but not yet for the keratinocyte-adapted A75/17-K CDV. These proteins were shown to have 
an important function on polymerase activity, which differs between the two virus strains. 
Concerning the V protein, it is well known to inhibit viral transcription in the 
Paramyxoviridae family. However, for the first time, the V protein was shown to increase and 
not to inhibit polymerase activity, and this was demonstrated for canine distemper virus only. 
This activating effect could be observed for both virus strains, the wild type and the Vero cell-
adapted strains. The V protein is mainly involved in viral pathogenicity in vivo by interacting 
with cellular proteins through its C-terminal conserved region called the zinc-finger domain, 
also found in transcription factors. As the mutations occured in the V protein did not have a 
clear in vitro effect, they probably play an important function in vivo in the loss of 
pathogenicity of A75/17-V CDV. 
The morbillivirus C proteins are necessary for an efficient RNA transcription (68) and the 
Sendai virus C protein decreases RNA synthesis. For canine distemper virus, the C proteins, 
which have the same amino acid sequence in A75/17 and A75/17-V CDV, influence 
polymerase activity differently. While the C protein of A75/17 has activating properties on its 
polymerase, the C protein of A75/17-V has an inhibitory effect on polymerase activity. As 
this effect could not be attributed to the C protein itself, it could be due to a different 
interaction of the C protein with the proteins forming the polymerase complex. For rinderpest 
virus, the C protein is known to directly interact with the L protein (210). The L protein 
sequence differing in one amino acid between the wild-type and the Vero cell-adapted strains, 
this amino acid change could disturb the interaction of the L protein with the C protein, then 
modifying the L protein function in polymerase activity.  
The abrogation of the C protein in the minireplicon assay changed the polymerase activity 
pattern of these two virus strains. But in the absence of the C protein and by comparing the 
overall polymerase activities of the wild-type and the Vero cell-adapted strains, the adapted 
polymerase gains activity and is then more active than the polymerase of the wild-type virus. 
This pattern change in polymerase activity could raise the question whether the C protein is 
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expressed for both virus strains. However, this has not been determined due to the lack of 
anti-C protein antibody. This result has to be confirmed at the level of virus infection and this 
study has been initiated using recombinant viruses devoid of C protein production. 
Unfortunately, this could only be done with the adapted virus but not with the wild-type virus 
as this rescue is not yet functional. However, the first recombinants confirmed the higher 
multiplication rate of the adapted virus in the absence of the C protein in Vero cells, also 
showing that the C protein is not essential for virus multiplication in vitro. Study of the 
recombinant virus showed that in the absence of the C protein expression, virus multiplication 
is enhanced in the first 48 hours, but then the absence of the C protein no longer influences 
virus replication, suggesting a possible function of the C protein early in infection. 
All these observations on polymerase activity are very interesting but many questions can 
only be answered by constructing different recombinant viruses containing the different 
mutations of either the wild-type or the adapted strains. This will then help to better 
understand canine distemper virus pathogenesis. 
 
4.7 CONCLUSION 
In conclusion, viral multiplication is a very complex field, which could be influenced 
positively and negatively by a large number of factors. First, the viral proteins shown in this 
work modulate polymerase activity. In addition, replication may also be regulated by host cell 
factors, which have not been considered in this project. The polycistronic gene encoding the 
P, V and C proteins has been extensively studies and all of them were shown to influence not 
only viral multiplication but also viral pathogenesis. In the future, many viruses will have to 
be constructed, which unfortunately were not available during my thesis. These will help 
understand the adaptation process; in particular the contribution of the M protein, which is 
certainly crucial for multiplication in Vero cells. These studies will help to better understand 
the molecular basis of pathogenesis and virulence of A75/17 CDV.  
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